Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_______________________________________________

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2023

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________to ________

Commission file number 000-56327

NewLake Capital Partners, Inc.

(Exact name of registrant as specified in its charter)


Maryland			83-4400045
(State or other jurisdiction of incorporation or organization)			(I.R.S. Employer Identification No.)

50 Locust Avenue, First Floor, New Canaan CT 06840			203-594-1402
(Address of principal executive offices)			(Registrants Telephone number)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

None

Securities registered pursuant to section 12(g) of the Act:

Common Stock, par value $0.01 per share

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer o	Accelerated filer o	Non-accelerated filer x	Smaller reporting company x
Emerging Growth Company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes o No x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes o No x

The number of shares of the registrant’s Common Stock, par value $0.01 per share, outstanding as of November 7, 2023 was 20,694,363.

Table of Contents

NewLake Capital Partners, Inc.

FORM 10-Q

September 30, 2023

TABLE OF CONTENTS


		Page No.

Part I Financial Information:
Item 1.	Financial Statements (Unaudited)
	Consolidated Balance Sheets	1
	Consolidated Statements of Operations	2
	Consolidated Statements of Equity	3
	Consolidated Statements of Cash Flows	5
	Notes to the Consolidated Financial Statements	6
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	26
	Special Note Regarding Forward Looking Information
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	40
Item 4.	Controls and Procedures	40
Part II Other Information:
Item 1.	Legal Proceedings	42
Item 1A.	Risk Factors	42
Item 2.	Unregistered Sales of Equity Securities and Issuer Purchases of Equity Securities	43
Item 3.	Defaults Upon Senior Securities	43
Item 4.	Mine Safety Disclosures	43
Item 5.	Other Information	43
Item 6.	Exhibits	43
Signatures		45

Table of Contents

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

NEWLAKE CAPITAL PARTNERS, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share amounts)


	September 30, 2023		December 31, 2022
Assets:	(Unaudited)
Real Estate
Land	$	21,397	$	21,427
Building and Improvements	382,087		378,047
Total Real Estate	403,484		399,474
Less Accumulated Depreciation	(28,931)		(19,736)
Net Real Estate	374,553		379,738
Cash and Cash Equivalents	31,065		45,192
In-Place Lease Intangible Assets, net	20,275		21,765
Loan Receivable	5,000		5,000
Property Held for Sale	1,949		—
Other Assets	2,300		2,554
Total Assets	$	435,142	$	454,249

Liabilities and Equity:

Liabilities:
Accounts Payable and Accrued Expenses	$	1,000	$	1,659
Revolving Credit Facility	1,000		1,000
Loan Payable, net	997		1,986
Dividends and Distributions Payable	8,231		8,512
Security Deposits	7,338		7,774
Rent Received in Advance	907		1,375
Other Liabilities	199		1,005
Total Liabilities	19,672		23,311

Commitments and Contingencies

Equity:
Preferred Stock, $0.01 Par Value, 100,000,000 Shares Authorized, 0 and 0 Shares Issued and Outstanding, Respectively	—		—
Common Stock, $0.01 Par Value, 400,000,000 Shares Authorized, 20,694,363 and 21,408,194 Shares Issued and Outstanding, Respectively	207		214
Additional Paid-In Capital	447,531		455,822
Accumulated Deficit	(39,635)		(32,487)
Total Stockholders' Equity	408,103		423,549

Noncontrolling Interests	7,367		7,389
Total Equity	415,470		430,938

Total Liabilities and Equity	$	435,142	$	454,249

The accompanying notes are an integral part of the consolidated financial statements

Table of Contents

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(In thousands, except share and per share amounts)


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2023		2022		2023		2022
Revenue:
Rental Income	$	11,297	$	11,595	$	33,637	$	30,217
Interest Income from Loans	131		434		390		2,301
Fees and Reimbursables	63		49		256		239
Total Revenue	11,491		12,078		34,283		32,757

Expenses:
Depreciation and Amortization Expense	3,568		3,630		10,698		9,113
General and Administrative Expenses:
Compensation Expense	1,173		1,040		3,450		5,100
Professional Fees	300		279		986		1,486
Other General and Administrative Expenses	467		419		1,537		1,387
Total General and Administrative Expenses	1,940		1,738		5,973		7,973
Total Expenses	5,508		5,368		16,671		17,086

Loss on Sale of Real Estate	—		—		—		(60)

Income From Operations	5,983		6,710		17,612		15,611

Other Income (Expenses):
Other Income	178		7		607		103
Interest Expense	(95)		(94)		(284)		(167)
Total Other Income (Expense)	83		(87)		323		(64)

Net Income	6,066		6,623		17,935		15,547



Net Income Attributable to Noncontrolling Interests	(108)		(113)		(312)		(262)

Net Income Attributable to Common Stockholders	$	5,958	$	6,510	$	17,623	$	15,285

Net Income Attributable to Common Stockholders Per Share - Basic	$	0.28	$	0.30	$	0.83	$	0.71

Net Income Attributable to Common Stockholders Per Share - Diluted	$	0.28	$	0.30	$	0.83	$	0.71

Weighted Average Shares of Common Stock Outstanding - Basic	21,199,638		21,428,905		21,330,046		21,417,149

Weighted Average Shares of Common Stock Outstanding - Diluted	21,582,314		21,802,487		21,710,101		21,815,763

The accompanying notes are an integral part of the consolidated financial statements

Table of Contents

NEWLAKE CAPITAL PARTNERS, INC.

CONSOLIDATED STATEMENTS OF EQUITY

(Unaudited)

(In thousands, except share amounts)


	Three Months Ended September 30, 2023
		Common Stock
		Shares	Par		Additional Paid-in Capital		Accumulated Deficit		Noncontrolling Interest		Total Equity
Balance as of June 30, 2023		21,302,515	$	213	$	455,143	$	(37,508)	$	7,328	$	425,176





Repurchase of Common Stock		(608,152)	(6)		(7,914)		—		—		(7,920)



Stock-Based Compensation		—	—		379		—		—		379



Dividends to Common Stock		—	—		—		(8,071)		—		(8,071)

Dividend Equivalents to Restricted Stock Units		—	—		—		(14)		—		(14)

Distributions to OP Unit Holders		—	—		—		—		(146)		(146)

Adjustment for Noncontrolling Interest Ownership in Operating Partnership		—	—		(77)		—		77		—

Net Income		—	—		—		5,958		108		6,066

Balance as of September 30, 2023		20,694,363	$	207	$	447,531	$	(39,635)	$	7,367	$	415,470


	Three Months Ended September 30, 2022
		Common Stock
		Shares	Par		Additional Paid-in Capital		Accumulated Deficit		Noncontrolling Interest		Total Equity
Balance as of June 30, 2022		21,318,637	$	213	$	456,083	$	(29,395)	$	7,422	$	434,323

Conversion of Vested RSUs to Common Stock		85,180	1		(1)		—		—		—



Stock-Based Compensation		—	—		280		—		—		280



Dividends to Common Stock		—	—		—		(7,919)		—		(7,919)

Dividend Equivalents to Restricted Stock Units		—	—		—		(7)		—		(7)

Distributions to OP Unit Holders		—	—		—		—		(137)		(137)

Adjustment for Noncontrolling Interest Ownership in Operating Partnership		—	—		(10)		—		10		—

Net Income		—	—		—		6,510		113		6,623

Balance as of September 30, 2022		21,403,817	$	214	$	456,352	$	(30,811)	$	7,408	$	433,163

The accompanying notes are an integral part of the consolidated financial statements

Table of Contents

NEWLAKE CAPITAL PARTNERS, INC.

CONSOLIDATED STATEMENTS OF EQUITY

(Unaudited)

(In thousands, except share amounts)


	Nine Months Ended September 30, 2023
		Common Stock
		Shares	Par		Additional Paid-in Capital		Accumulated Deficit		Noncontrolling Interest		Total Equity
Balance as of December 31, 2022		21,408,194	$	214	$	455,822	$	(32,487)	$	7,389	$	430,938





Repurchase of Common Stock		(713,831)	(7)		(9,247)		—		—		(9,254)



Stock-Based Compensation		—	—		1,060		—		—		1,060



Dividends to Common Stock		—	—		—		(24,709)		—		(24,709)

Dividend Equivalents to Restricted Stock Units		—	—		—		(62)		—		(62)

Distributions to OP Unit Holders		—	—		—		—		(438)		(438)

Adjustment for Noncontrolling Interest Ownership in Operating Partnership		—	—		(104)		—		104		—

Net Income		—	—		—		17,623		312		17,935

Balance as of September 30, 2023		20,694,363	$	207	$	447,531	$	(39,635)	$	7,367	$	415,470


	Nine Months Ended September 30, 2022
		Common Stock
		Shares	Par		Additional Paid-in Capital		Accumulated Deficit		Noncontrolling Interest		Total Equity
Balance as of December 31, 2021		21,235,914	$	213	$	450,916	$	(23,574)	$	11,780	$	439,335

Conversion of Vested RSUs to Common Stock		88,182	1		125		—		(126)		—

Conversion of OP Units to Common Stock		79,721	—		1,586		—		(1,586)		—

Stock-Based Compensation		—	—		1,201		—		—		1,201



Dividends to Common Stock		—	—		—		(22,410)		—		(22,410)

Dividend Equivalents to Restricted Stock Units		—	—		—		(112)		—		(112)

Distributions to OP Unit Holders		—	—		—		—		(398)		(398)

Adjustment for Noncontrolling Interest Ownership in Operating Partnership		—	—		2,524		—		(2,524)		—

Net Income		—	—		—		15,285		262		15,547

Balance as of September 30, 2022		21,403,817	$	214	$	456,352	$	(30,811)	$	7,408	$	433,163

The accompanying notes are an integral part of the consolidated financial statements

Table of Contents

NEWLAKE CAPITAL PARTNERS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)


	For the Nine Months Ended
	September 30, 2023		September 30, 2022
Cash Flows from Operating Activities:
Net Income	$	17,935	$	15,547
Adjustments to Reconcile Net Income to Net Cash Provided by Operating Activities:
Stock-Based Compensation	1,060		1,201
Loss on Sale of Real Estate	—		60
Depreciation and Amortization Expense	10,698		9,113
Amortization of Debt Issuance Costs	201		72
Amortization of Debt Discount	10		20

Non-Cash Application of Security Deposit	(945)		—
Changes in Assets and Liabilities
Other Assets	22		(1,618)
Accounts Payable and Accrued Expenses	(659)		577
Security Deposits	510		1,263
Interest Reserve	—		(2,144)
Rent Received in Advance	(468)		(567)
Other Liabilities	(761)		—
Net Cash Provided by Operating Activities	27,603		23,524

Cash Flows from Investing Activities:



Funding of Tenant Improvements	(5,609)		(43,518)
Investment in Loans Receivable	—		(5,000)
Acquisition of Real Estate	(350)		(35,419)
Disposition of Real Estate	—		761
Net Cash Used in Investing Activities	(5,959)		(83,176)

Cash Flows from Financing Activities:


Repurchase of Common Stock	(9,254)		—
Common Stock Dividends Paid	(24,987)		(21,074)
Restricted Stock Units Dividend Equivalents Paid	(65)		(147)
Distributions to OP Unit Holders	(437)		(401)

Borrowings from Revolving Credit Facility	—		1,000
Principal Repayment on Loan Payable	(1,000)		(1,800)
Deferred Financing Costs	(28)		—
Net Cash Used in Financing Activities	(35,771)		(22,422)

Net (Decrease) in Cash and Cash Equivalents	(14,127)		(82,074)
Cash and Cash Equivalents - Beginning of Period	45,192		127,097

Cash and Cash Equivalents - End of Period	$	31,065	$	45,023
Supplemental Disclosure of Cash Flow Information:
Interest Paid	$	123	$	15
Supplemental Disclosure of Non-Cash Investing and Financing Activities:
Dividends and Distributions Declared, Not Paid	$	8,231	$	8,064


Conversion of Mortgage Loan Receivable to Real Estate	$	—	$	30,000


Operating lease liability for obtaining right of use asset	$	—	$	277

The accompanying notes are an integral part of the consolidated financial statements

Table of Contents

NEWLAKE CAPITAL PARTNERS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2023

(Unaudited)

Note 1 - Organization

NewLake Capital Partners, Inc. (the “Company”), a Maryland corporation, was formed on April 9, 2019, originally as GreenAcreage Real Estate Corp. (“GARE”). The Company is an internally managed Real Estate Investment Trust (“REIT”) focused on providing long-term, single-tenant, triple-net sale-leaseback and build-to-suit transactions for the cannabis industry. The Company conducts its business through its subsidiary, NLCP Operating Partnership LP, a Delaware limited partnership (the “Operating Partnership” or “OP”). The Company holds a controlling equity interest in the Operating Partnership and is the sole general partner. The Company's common stock trades on the OTCQX® Best Market operated by the OTC Markets Group, Inc., under the symbol “NLCP”.

Note 2 - Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation

The consolidated financial statements include the accounts of the Company, the Operating Partnership, as well as wholly owned subsidiaries of the Operating Partnership and variable interest entities ("VIEs") in which the Company is considered the primary beneficiary. The accompanying unaudited financial statements and related notes have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) for interim financial statements and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. All significant intercompany balances and transactions have been eliminated in the consolidated financial statements. In management's opinion, all adjustments (which include only normal recurring adjustments) necessary to present fairly the Company’s financial position, results of operations and cash flows have been made. The results of operations for the three and nine months ended September 30, 2023 are not necessarily indicative of the operating results for the full year or any future period. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, and filed with the Securities and Exchange Commission (“SEC”) on March 9, 2023.

Substantially all of the Company's asset are held by and all of its operations are conducted through the Operating Partnership. The Company is the sole managing general partner of the Operating Partnership. Noncontrolling investors in the Operating Partnership are included in Noncontrolling Interest in the Company's consolidated financial statements. Refer to Note 8 for details. The Operating Partnership is a VIE because the holders of limited partnership interests do not have substantive kick-out rights or participating rights. Furthermore, the Company is the primary beneficiary of the Operating Partnership because it has the obligation to absorb losses and the right to receive benefits from the Operating Partnership and the exclusive power to direct the activities of the Operating Partnership. As of September 30, 2023 and December 31, 2022, the assets and liabilities of the Company and the Operating Partnership are substantially the same, as the Company does not have any significant assets other than its investment in the Operating Partnership.

Use of Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Management will adjust such estimates when facts and circumstances dictate. Such estimates include, but are not limited to, useful lives for depreciation of property, the fair value and impairment of property and in-place lease intangibles acquired, and the fair value of stock-based compensation. Actual results could differ from those estimates.

Table of Contents

NEWLAKE CAPITAL PARTNERS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2023

(Unaudited)

Note 2 - Basis of Presentation and Summary of Significant Accounting Policies (continued)

Reclassification

Certain prior year balances have been reclassified to conform to the Company's current year presentation.

Significant Accounting Policies

There have been no changes to the Company's accounting polices included in Note 2 to the Consolidated Financial Statements of the Company's Annual Report on Form 10-K for the year ended December 31, 2022, except as follows:

Property Held for Sale

The Company classifies real estate held for sale when the following criteria are met: (i) management commits to a plan to sell the property, (ii) the property is available for sale, (iii) the property is actively being marketed for sale at a price that is reasonable, (iv) the sale of the property within one year is considered probable, and (v) significant change to the plan to sell the property is not expected. A real estate asset held for sale is classified as "Property Held for Sale" in the consolidated balance sheets. A property classified as held for sale is no longer depreciated and is required to be reported at the lower of its carrying value or its fair value less cost to sell.

Financial Instruments - Credit Losses

The Company adopted Accounting Standards Codification ("ASC") ASC 326, Financial Instruments - Credit Losses ("CECL") on January 1, 2023, which did not have a material impact to its financial statements. The CECL expected loss model requires an allowance for all expected credit losses for the life of a loan be recognized when the loan is either originated or acquired. The allowance for credit losses is a valuation account that is deducted from, or added to, the amortized cost basis of the financial asset(s) to present the net amount expected to be collected on the financial asset(s). At each reporting period, the company will update its estimate and adjust the allowance for credit losses accordingly. Increases in the allowance are recorded through net income as credit loss expense. Decreases in the allowance are recorded through net income as a reversal of credit loss expense. This standard does not specify a specific measurement technique for estimating expected credit losses. Approaches can vary based on a variety of factors. The Company generally uses a discounted cash flow model approach to determine the credit loss, if any, for its financial instruments subject to the CECL guidance.

Table of Contents

NEWLAKE CAPITAL PARTNERS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2023

(Unaudited)

Note 3 - Real Estate

As of September 30, 2023, the Company owned 32 properties, including one that is classified as held for sale, located in 12 states. The following table presents the Company's held for investment real estate portfolio as of September 30, 2023 (dollars in thousands):


Tenant		Market	Site Type	Land		Building and Improvements		Total Real Estate		Accumulated Depreciation		Net Real Estate
Acreage		Connecticut	Dispensary	$	395	$	534	$	929	$	(71)	$	858
Acreage		Massachusetts	Cultivation	481		9,310		9,791		(1,091)		8,700
Acreage		Pennsylvania	Cultivation	952		9,209		10,161		(1,042)		9,119
Ayr Wellness, Inc.		Nevada	Cultivation	1,002		12,577		13,579		(484)		13,095
Ayr Wellness, Inc.		Pennsylvania	Cultivation	2,964		11,565		14,529		(512)		14,017
Bloom Medicinal	(1)	Missouri	Cultivation	948		14,346		15,294		(419)		14,875
Calypso Enterprises		Pennsylvania	Cultivation	1,486		28,514		30,000		(1,168)		28,832
Columbia Care		California	Dispensary	1,082		2,692		3,774		(219)		3,555
Columbia Care		Illinois	Dispensary	162		1,053		1,215		(83)		1,132
Columbia Care		Illinois	Cultivation	801		10,560		11,361		(838)		10,523
Columbia Care		Massachusetts	Dispensary	108		2,212		2,320		(194)		2,126
Columbia Care		Massachusetts	Cultivation	1,136		12,690		13,826		(1,348)		12,478
Cresco Labs		Illinois	Cultivation	276		50,456		50,732		(5,368)		45,364
Curaleaf		Connecticut	Dispensary	184		2,748		2,932		(232)		2,700
Curaleaf		Florida	Cultivation	388		75,595		75,983		(5,765)		70,218
Curaleaf		Illinois	Dispensary	69		525		594		(46)		548
Curaleaf		Illinois	Dispensary	65		959		1,024		(87)		937
Curaleaf		Illinois	Dispensary	606		1,128		1,734		(101)		1,633
Curaleaf		Illinois	Dispensary	281		3,072		3,353		(266)		3,087
Curaleaf		North Dakota	Dispensary	779		1,395		2,174		(124)		2,050
Curaleaf		Ohio	Dispensary	574		2,788		3,362		(281)		3,081
Curaleaf		Pennsylvania	Dispensary	877		1,041		1,918		(118)		1,800
Curaleaf		Pennsylvania	Dispensary	216		2,011		2,227		(174)		2,053
Greenlight	(2)	Arkansas	Dispensary	238		1,919		2,157		(166)		1,991
Mint	(3)	Arizona	Cultivation	2,400		12,907		15,307		—		15,307
Organic Remedies		Missouri	Cultivation	204		20,897		21,101		(1,910)		19,191
PharmaCann		Massachusetts	Dispensary	411		1,701		2,112		(261)		1,851
PharmaCann		Ohio	Dispensary	281		1,269		1,550		(33)		1,517
PharmaCann		Pennsylvania	Dispensary	44		1,271		1,315		(100)		1,215
Revolutionary Clinics		Massachusetts	Cultivation	926		41,934		42,860		(2,768)		40,092
Trulieve		Pennsylvania	Cultivation	1,061		43,209		44,270		(3,662)		40,608
Total Real Estate(4)				$	21,397	$	382,087	$	403,484	$	(28,931)	$	374,553

(1) A portion of this investment is currently under development. Once the expansion is completed and placed in service, the Company will begin depreciating this part of the property.

(2) GL Partners, Inc. (Greenlight) took over as tenant, however Curaleaf remains the guarantor subject to certain conditions in the lease agreement.

(3) This property is under development. Once completed and placed in service, the Company will start depreciating this property.

(4) The table does not include one property held for sale.

Table of Contents

NEWLAKE CAPITAL PARTNERS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2023

(Unaudited)

Note 3 - Real Estate (continued)

Real Estate Acquisitions

In March 2023, the Company exercised its option and invested approximately $350 thousand to acquire one parcel of land and committed to fund $16.2 million to expand an existing cultivation facility in Missouri (refer to the Tenant Improvement ("TI") table below).

The following table presents the real estate acquisition for the nine months ended September 30, 2023 (in thousands):

Tenant

Market

Site Type

Closing Date

Real Estate Acquisition Costs

Bloom Medicinal

Missouri

Cultivation

March 3, 2023

350

(1)

Total

350

(1)The Company exercised its option to purchase the adjacent parcel of land to expand its cultivation facility in Missouri and has committed to fund $16.2 million for the expansion.

During the year ended December 31, 2022, the Company invested approximately $67.0 million to acquire four cultivation facilities and one dispensary. The following table presents the real estate acquisitions for the year ended December 31, 2022 (in thousands):

Tenant

Market

Site Type

Closing Date

Real Estate Acquisition Costs(1)

Bloom Medicinal

Missouri

Cultivation

April 1, 2022

7,301

(2)

Ayr Wellness, Inc.

Pennsylvania

Cultivation

June 30, 2022

14,529

Ayr Wellness, Inc.

Nevada

Cultivation

June 30, 2022

13,579

Calypso Enterprises

Pennsylvania

Cultivation

August 5, 2022

30,000

(3)

PharmaCann

Ohio

Dispensary

November 3, 2022

1,550

Total

66,959

(1) Includes the purchase price (and in some cases, transaction costs that have been capitalized into the purchase price) and TI commitments funded at closing, if any, as of December 31, 2022. Excludes TI commitments not funded as of December 31, 2022.

(2) Includes approximately $5.0 million of TI funded at closing of the property.

(3) The Company entered into a $30.0 million mortgage loan on October 29, 2021, which converted to a sale-leaseback on August 5, 2022.

Conversion of Mortgage Loan

The Company funded a $30.0 million mortgage loan to Hero Diversified Associates, Inc. (“HDAI" or "Calypso") on October 29, 2021. On August 5, 2022 the mortgage loan converted to a twenty year sale-leaseback and the Company recorded land and building and improvements which have been included in "Total Real Estate" on the consolidated balance sheets.

Table of Contents

NEWLAKE CAPITAL PARTNERS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2023

(Unaudited)

Note 3 - Real Estate (continued)

Tenant Improvements Funded

During the nine months ended September 30, 2023, the Company funded approximately $5.6 million of tenant improvements. The following table presents the tenant improvements funded for the nine months ended September 30, 2023 (in thousands):


Tenant	Market	Site Type	Closing Date	TI Funded			Unfunded Commitments
Mint	Arizona	Cultivation	June 24, 2021	$	2,366		$	5,703	(1)
Organic Remedies	Missouri	Cultivation	December 20, 2021	282			—
Bloom Medicinal	Missouri	Cultivation	April 1, 2022	2,961		(2)	13,722
Ayr Wellness, Inc.	Pennsylvania	Cultivation	June 30, 2022	—			750




Total				$	5,609		$	20,175

(1) Effective June 1, 2023, the lease agreement was amended to include an additional TI commitment of approximately $6.5 million.

(2)Approximately $534 thousand of the TI funded related to our commitment prior to exercising our option related to the additional parcel.

During the year ended December 31, 2022, the Company funded approximately $45.2 million of tenant improvements. The following table presents the tenant improvements funded for the year ended December 31, 2022 (in thousands):

Tenant

Market

Site Type

Closing Date

TI Funded

Unfunded Commitments

Curaleaf

Florida

Cultivation

August 4, 2020

20,983

(1)

—

Mint

Massachusetts

Cultivation

April 1, 2021

349

—

Mint

Arizona

Cultivation

June 24, 2021

7,415

1,554

(2)

PharmaCann

Massachusetts

Dispensary

March 17, 2021

—

Trulieve

Pennsylvania

Cultivation

March 17, 2021

7,046

(3)

—

Organic Remedies

Missouri

Cultivation

December 20, 2021

4,745

282

Bloom Medicinal

Missouri

Cultivation

April 1, 2022

4,682

534

(4)

Ayr Wellness, Inc.

Pennsylvania

Cultivation

June 30, 2022

—

750

Total

45,245

3,120

(1) On June 16, 2022, the Company funded the expansion of an existing property.

(2) The tenant had been paying rent for the remaining commitment since July 2022 in accordance with the lease agreement.

(3) The tenant had been paying rent for the TI since December 2021 in accordance with the lease agreement. As of May 2022, the TI had been fully funded.

(4) The unfunded commitment did not include an option, because the Company did not have an obligation to acquire the adjacent property from an existing tenant and fund TIs.

Disposal of Real Estate

There were no sales of real estate during the nine months ended September 30, 2023.

Table of Contents

NEWLAKE CAPITAL PARTNERS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2023

(Unaudited)

Note 3 - Real Estate (continued)

On March 21, 2022, the Company sold one of its Massachusetts properties for approximately $0.8 million, which was leased to PharmaCann. The Company recognized a loss on sale of the property of $60 thousand. PharmaCann continued to pay rent for the sold Massachusetts property through increased rent payments from each of the remaining two properties leased by PharmaCann until a suitable replacement property was found. In November 2022 a replacement property was acquired by the Company and leased to PharmaCann.

Real Estate Held for Sale

The Company is under contract with a broker to sell a property with a carrying amount of $1.9 million located in Massachusetts leased to Mint. The property is available for immediate sale in its present condition and management expects the property will sell within one year, accordingly the property is classified in "Property Held for Sale" in the accompanying consolidated balance sheet. The lease agreement contains a make-whole provision. As of September 30, 2023, the property continues to be recorded at its carrying value.

On August 25, 2023, the Company entered into a purchase and sale agreement for the sale of its Massachusetts property that is leased to Mint, subject to customary buyer's due diligence. In connection with the agreement, the buyer deposited $100,000 into an escrow account. The escrow deposit was fully refundable if the contract was terminated during the due diligence period. As of September 30, 2023, the due diligence period had expired and $75,000 of the escrow deposit was non-refundable in the event the buyer terminated the contract. The escrow deposit was not recorded in the accompanying consolidated balance sheet as of September 30, 2023. The sale closed subsequent to September 30, 2023, refer to Note 15 - Subsequent Events for details.

Construction in Progress

As of September 30, 2023 and December 31, 2022, construction in progress was $15.3 million and $12.1 million, respectively, and is classified in "Buildings and Improvements" in the accompanying consolidated balance sheets.

Depreciation and Amortization

Depreciation expense for the three months ended September 30, 2023 and 2022 was $3.1 million and $3.1 million, respectively. Depreciation expense for the nine months ended September 30, 2023 and 2022, was $9.2 million and $7.6 million, respectively.

Amortization of the Company’s acquired in-place lease intangible assets was approximately $0.5 million for both the three months ended September 30, 2023 and 2022. Amortization of the Company’s acquired in-place lease intangible assets was approximately $1.5 million for both the nine months ended September 30, 2023 and 2022. The acquired in-place lease intangible assets have a weighted average remaining amortization period of 10.5 years.

Table of Contents

NEWLAKE CAPITAL PARTNERS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2023

(Unaudited)

In-place Leases

The following table presents the future amortization of the Company’s acquired in-place leases as of September 30, 2023 (in thousands):


Year	Amortization Expense
2023 (three months ending December 31, 2023)	$	496
2024	1,985
2025	1,985
2026	1,985
2027	1,985
Thereafter	11,839
Total	$	20,275

Impairment

The Company reviewed tenant activities and changes in the business condition of all of its properties and reviewed the existence of potential triggering events for impairment indicators to determine if there were impairments at any property. Based on our review, as of September 30, 2023 and September 30, 2022, no impairment losses were recognized.

Note 4 - Leases

As Lessor

The Company's properties are leased to single tenants on a long-term, triple-net basis, which obligates the tenant to be responsible for the ongoing expenses of a property, in addition to its rent obligations. Under certain circumstances the Company will pay for certain expenses on behalf of the tenant and the tenant is required to reimburse the Company. The presentation in the statements of operations for these expenses are gross where the Company records revenue and a corresponding reimbursable expense. Expenses paid directly by a tenant are not reimbursable and therefore not reflected in the statement of operations. The amount may differ due to timing. The revenues associated with the reimbursable expenses were classified in "Fees and Reimbursables" in the accompanying consolidated statements of operations. For the three months ended September 30, 2023, and 2022 the reimbursable revenues were $14.5 thousand and $4.9 thousand, respectively. For the nine months ended September 30, 2023, and 2022 the reimbursable revenues were $111.9 thousand, and $138.6 thousand, respectively. The reimbursable expenses were classified in "Other General and Administrative Expenses" in the accompanying consolidated statements of operations. The reimbursable expenses for the three months ended September 30, 2023 and 2022 were $77.9 thousand and $14.8 thousand, respectively. For the nine months ended September 30, 2023 and 2022 reimbursable expenses were $228.1 thousand, and $148.4 thousand, respectively.

The Company's tenants operate in the cannabis industry. All of the Company's leases generally contain annual increases in rent (typically between 2% and 3%) over the expiring rental rate at the time of expiration. Certain leases of the Company also contain a Tenant Improvement Allowance (“TIA”). TIA is generally available to be funded between 12 and 18 months. In some leases, the tenant becomes liable to pay rent as if the full TIA has been funded, even if there are still unfunded commitments. TIA also contains annual increases which generally increase at the same rate as base rent, per the lease agreement. Certain of the Company's leases provide the lessee with a right of first refusal or right of first offer in the event the Company markets the leased property for sale. Two of the Company’s leases that were entered into in December 2019 provide the lessee with a purchase option to

Table of Contents

NEWLAKE CAPITAL PARTNERS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2023

(Unaudited)

purchase the leased property at the end of the initial lease term in December 2029, subject to the satisfaction of certain conditions. The purchase option provision allows the lessee to purchase the leased property for an amount based on the fair market value of the Company's investment. As of September 30, 2023, the Company's gross investment in these two properties was approximately $6.3 million.

The following table presents the future contractual minimum rent under the Company’s operating leases as of September 30, 2023 (in thousands):


Year	Contractual Minimum Rent(1)
2023 (three months ending December 31, 2023)	$	12,463
2024	52,076
2025	54,333
2026	55,734
2027	57,171
Thereafter	609,709
Total	$	841,486

(1) This table includes future contractual rent from one non-performing tenant who did not pay rent for the nine months ended September 30, 2023. Subsequent to September 30, 2023, the Company reached an agreement to amend the existing lease agreement. Refer to Note 15 - Subsequent Events for details.

Concentration of Credit Risk

The ability of any of the Company's tenants to honor the terms of its lease are dependent upon the economic, regulatory, competitive, natural and social factors affecting the community in which that tenant operates.

Table of Contents

NEWLAKE CAPITAL PARTNERS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2023

(Unaudited)

Note 4 - Leases (continued)

The following table presents the five tenants in the Company's portfolio that represented the largest percentage of the Company's recognized rental income for each of the periods presented:


For the Three Months Ended September 30,
2023				2022
Tenant	Number of Leases		Percentage of Rental Income(1)	Tenant		Number of Leases	Percentage of Rental Income(1)
Curaleaf	10		25%	Curaleaf		10	25%
Cresco Labs	1		15%	Cresco Labs		1	17%
Trulieve	1		12%	Trulieve		1	14%
Columbia Care	5		9%	Revolutionary Clinics	(3)	1	13%
Calypso	1	(2)	8%	Columbia Care		5	10%

(1) Calculated based on rental income received during the period. This amount excludes revenue from fees and reimbursements.

(2) This tenant held a mortgage loan as of the three months ended September 30, 2022, therefore the Company received interest income rather than rental income during that period. In August 2022, the mortgage loan converted to a twenty year sale-leaseback.

(3) This tenant is in default of its lease agreement. For the three months ended September 30, 2023, the Company applied approximately $315 thousand of their security deposit towards the outstanding rent.


For the Nine Months Ended September 30,
2023				2022
Tenant	Number of Leases		Percentage of Rental Income(1)	Tenant		Number of Leases	Percentage of Rental Income(1)
Curaleaf	10		25%	Curaleaf		10	25%
Cresco Labs	1		14%	Cresco Labs		1	16%
Trulieve	1		12%	Trulieve		1	13%
Columbia Care	5		9%	Revolutionary Clinics	(3)	1	13%
Calypso	1	(2)	8%	Columbia Care		5	10%

(1) Calculated based on rental income received during the period. This amount excludes revenue from fees and reimbursements.

(2) This tenant held a mortgage loan as of the nine months ended September 30, 2022, therefore the Company received interest income rather than rental income during that period. In August 2022, the mortgage loan converted to a twenty year sale-leaseback.

(3) This tenant failed to pay rental income during the nine months ended September 30, 2023. A security deposit of approximately $945 thousand was applied towards the outstanding rent.

Non-Performing Tenant

For the nine months ended September 30, 2023, Revolutionary Clinics failed to pay contractual rent under one lease agreement. The Company is currently in discussion with the tenant to negotiate a resolution, which could include rent deferrals, rent concessions or other concessions. The Company held a security deposit of approximately three months of contractual rent, of which the Company applied $945 thousand towards the outstanding rent during the nine months ended September 30, 2023. Approximately $315 thousand of security deposit remains for future application. Subsequent to September 30, 2023, the Company reached an agreement to restructure the existing lease agreement. Refer to Note 15 - Subsequent Events for details.

Table of Contents

NEWLAKE CAPITAL PARTNERS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2023

(Unaudited)

Note 4 - Leases (continued)

As Lessee

As of September 30, 2023, the Company was the lessee under one office lease that qualifies under the right-of-use ("ROU") model. Upon entering into the lease in June 2022, the Company recorded a ROU asset of $273 thousand which is classified in “Other Assets” and a lease liability, which is classified in "Other Liabilities" in the accompanying consolidated balance sheets. The ROU asset is amortized over the remaining lease term. The amortization is made up of the principal amortization under the lease liability plus or minus the straight-line adjustment of the operating lease rent.

The following table presents the future contractual rent obligations as lessee as of September 30, 2023 (in thousands):


Year	Contractual Base Rent
2023 (three months ended December 31, 2023)	$	19
2024	75
2025	77
2026	52


Total Minimum Lease Payments	$	223
Less: Amount Discounted Using Incremental Borrowing Rate	$	84
Total Lease Liability	$	139

As of September 30, 2023, the weighted-average discount rate used to calculate the lease liability was 5.65% and the remaining lease term was 2.92 years.

Note 5 – Loan Receivable

The Company funded a $5.0 million unsecured loan to Bloom Medicinals on June 10, 2022. The loan initially bore interest at a rate of 10.25% and is structured to increase annually in April by the product of 1.0225 times the interest rate in effect immediately prior to the anniversary date. The loan can be prepaid at any time without penalty and matures on June 30, 2026. The loan is cross defaulted with their lease agreement with the Company. As of September 30, 2023, the aggregate principal amount outstanding on the unsecured loan receivable was $5.0 million with an interest rate of 10.48%.

CECL Reserve

The Company adopted CECL on January 1, 2023, which did not have a material impact on its financial statements. The Company has only one $5.0 million unsecured loan (discussed above) subject to this guidance, since originating loans is not a core asset class. Estimating the CECL reserve requires significant judgement and based on the Company's analysis as of September 30, 2023, the reserve was de-minimis.

Table of Contents

NEWLAKE CAPITAL PARTNERS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2023

(Unaudited)

Note 6 – Financings

Seller Financing

In connection with the purchase and leaseback of a cultivation facility in Chaffee, Missouri on December 20, 2021, the Company entered into a $3.8 million loan payable to the seller, which is an independent third party from the tenant. The loan bears interest at a rate of 4.0% per annum. Principal on the loan is payable in annual installments of which $1.8 million and $1.0 million were paid in January 2022 and January 2023, respectively. The remaining principal of $1.0 million and accrued interest is payable in January 2024. The loan's outstanding balance as of September 30, 2023 was $1.0 million and the remaining unamortized discount was $3.4 thousand.

Revolving Credit Facility

On May 6, 2022, the Company's Operating Partnership entered into a loan and security agreement (the “Loan and Security Agreement”) with a commercial federally regulated bank, as a lender and as agent for lenders that become party thereto from time to time (the “Agent”). The Loan and Security Agreement matures on May 6, 2027. The Loan and Security Agreement provides, subject to the Accordion Feature described below, $30.0 million in aggregate commitments for secured revolving loans (“Revolving Credit Facility”), the availability of which is based on a borrowing base consisting of fee simple owned real properties that satisfy eligibility criteria specified in the Loan and Security Agreement and the lease income thereunder which are owned by certain subsidiaries of the Operating Partnership.

On July 29, 2022, the Operating Partnership, entered into an amendment to the Revolving Credit Facility, amending the Loan and Security Agreement, to increase the aggregate commitment under the Revolving Credit Facility from $30.0 million to $90.0 million and added two additional lenders. The Loan and Security Agreement also allows the Company, subject to certain conditions, to request additional revolving incremental loan commitments such that the Revolving Credit Facility may be increased to a total aggregate principal amount of up to $100.0 million. Borrowings under the Revolving Credit Facility may be voluntarily prepaid and re-borrowed, subject to certain fees.

The Revolving Credit Facility bears a fixed rate of 5.65% for the first three years and thereafter a variable rate based upon the greater of (a) the Prime Rate quoted in the Wall Street Journal (Western Edition) (“Base Rate”) plus an applicable margin of 1.0% or (b) 4.75%.

As of September 30, 2023, the Company had approximately $1.0 million in borrowings under the Revolving Credit Facility and $89.0 million in funds available to be drawn, subject to sufficient collateral in the borrowing base.

The facility is subject to certain liquidity and operating covenants and includes customary representations and warranties, affirmative and negative covenants and events of default. As of September 30, 2023, the Company complied with the terms of such covenants.

Note 7 - Related Party Transactions

Merger Agreement

In connection with the merger, pursuant to which we combined the Company with a separate company that owned a portfolio of dispensaries and cultivation facilities utilized in the cannabis industry, and renamed ourselves NewLake Capital Partners, Inc. (the "Merger") on March 17, 2021, the Company entered into an Investor Rights Agreement (the "Investor Rights Agreement"). The Investor Rights Agreement provides the stockholders party thereto with certain rights with respect to the nomination of members to the Company's board of directors. Prior to the completion of the Company's IPO, pursuant to the Investor Rights Agreement, HG Vora Capital Management,

Table of Contents

NEWLAKE CAPITAL PARTNERS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2023

(Unaudited)

Note 7 - Related Party Transactions (continued)

LLC (“HG Vora”) had the right to nominate four directors to our board of directors. Following the completion of our IPO, for so long as HG Vora owns (i) at least 9% of our issued and outstanding common stock for 60 consecutive days, HG Vora may nominate two of the members of our board of directors, and (ii) at least 5% of our issued and outstanding common stock for 60 consecutive days, HG Vora may nominate one member of our board of directors. If HG Vora owns less than 5% of our issued and outstanding common stock for 60 consecutive days, then HG Vora may not nominate any members of our board of directors pursuant to the Investor Rights Agreement.

Following the completion of our IPO, the West Stockholders may nominate one member of our board of directors for so long as the West Stockholders own in the aggregate at least 5% of the issued and outstanding shares of our common stock. If the West Stockholders own in the aggregate less than 5% of our issued and outstanding common stock for 60 consecutive days, then the West Stockholders may not nominate any members of our board of directors pursuant to the Investor Rights Agreement.

Following the completion of our IPO, Pangea may nominate one member of our board of directors for so long as Pangea owns at least 4% of our issued and outstanding common stock for 60 consecutive days. If Pangea owns less than 4% of our issued and outstanding common stock for 60 consecutive days, then Pangea may not nominate any members of our board of directors pursuant to the Investor Rights Agreement.

Note 8 - Noncontrolling Interests

The Company's noncontrolling interests represent limited partnership interest in the Operating Partnership not held by the Company. Noncontrolling interests represented 1.7% ownership in the Operating Partnership at September 30, 2023 and December 31, 2022.

The following table presents the activity for the Company’s noncontrolling interests issued by the Operating Partnership for the nine months ended September 30, 2023 and the year ended December 31, 2022:


	September 30, 2023			December 31, 2022
	OP Units	Noncontrolling Interests %		OP Units	Noncontrolling Interests %
Balance at January 1,	373,582	1.7	%	453,303	2.1	%




OP Units Converted	—	—	%	(79,721)	(0.4)	%
Balance at End of Period	373,582	1.7	%	373,582	1.7	%

Note 9 - Stock Based Compensation

The Company's board of directors adopted the 2021 Equity Incentive Plan (the “Plan”), to provide employees of the Company and its subsidiaries, certain consultants and advisors who perform services for the Company or its subsidiaries, and non-employee members of the board of directors of the Company with the opportunity to receive grants of incentive stock options, nonqualified stock options, stock appreciation rights, stock awards, stock units, other stock-based awards, and cash awards to enable the Company to motivate, attract and retain the services of directors, officers and employees considered essential to the long term success of the Company. Under the terms of the Plan, the aggregate number of shares of awards will be no more than 2,275,727 shares. If and to the extent shares of awards granted under the Plan, expire or are canceled, forfeited, exchanged or surrendered without having been exercised, or if any stock awards, stock units or other stock-based awards are forfeited, terminated or otherwise not paid in full, the shares subject to such grants shall again be available for issuance or transfer under the Plan. The Plan has a term of ten years until August 12, 2031. As of September 30, 2023, there were approximately 1,912,535 shares available for issuance under the Plan.

Table of Contents

NEWLAKE CAPITAL PARTNERS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2023

(Unaudited)

Note 9 - Stock Based Compensation (continued)

Restricted Stock Units

Restricted Stock Units ("RSUs") are granted to certain directors, officers and employees of the Company. Per the terms of the agreements, certain director RSUs that vest cannot be converted until the director separates from the Company. Total outstanding RSUs as of September 30, 2023 and 2022 were 106,820 and 54,175, respectively.

Table of Contents

NEWLAKE CAPITAL PARTNERS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2023

(Unaudited)

Note 9 - Stock Based Compensation (continued)

Unvested Restricted Stock Units

The following table sets forth the Company's unvested RSU activity for the nine months ended September 30,:


	For the Nine Months Ended September 30,
	2023			2022
	Number of Unvested Shares of RSUs	Weighted Average Grant Date Fair Value Per Share		Number of Unvested Shares of RSUs	Weighted Average Grant Date Fair Value Per Share
Balance at January 1,	29,255	$	22.89	45,018	$	27.49
Granted	59,031	$	12.87	19,362	$	20.54
Forfeited	—	$	—	(8,566)	27.49
Vested	(18,318)	$	23.54	(20,173)	$	27.49
Balance at September 30,	69,968	$	15.15	35,641	$	23.71

Vested Restricted Stock Units

The following table sets forth the Company's vested RSU activity for the nine months ended September 30,:


	For the Nine Months ended September 30,
	2023			2022
	Number of Vested Shares of RSUs	Weighted Average Grant Date Fair Value Per Share		Number of Vested Shares of RSUs	Weighted Average Grant Date Fair Value Per Share
Balance at January 1,	18,534	$	23.93	127,176	$	21.08
Vested	18,318	20.14		9,493	27.49
Converted	—	—		(118,135)	21.15
Balance at September 30,	36,852	$	22.05	18,534	$	23.93

Each RSU represents the right to receive one share of common stock upon vesting. Each RSU is also entitled to receive a dividend equivalent payment equal to the dividend paid on one share of common stock upon vesting. Unearned dividend equivalents on unvested RSUs as of September 30, 2023 and 2022 were $88,756 and $35,850, respectively.

The amortization of compensation costs for the awards of RSUs are classified in "Compensation Expense" in the accompanying consolidated statements of operations and amounted to approximately $0.5 million and $0.8 million for the nine months ended September 30, 2023 and 2022, respectively. Included in the $0.8 million of stock-based compensation for the nine months ended September 30, 2022 is approximately $0.2 million of accelerated expense related to the retirement and separation of certain officers. There was no accelerated expensed for the nine months ended September 30, 2023. The amortization of compensation costs for the awards of RSUs amounted to approximately $0.2 million and $0.1 million for the three months ended September 30, 2023 and 2022, respectively. The remaining unrecognized compensation cost of approximately $0.7 million for RSU awards is expected to be recognized over a weighted average amortization period of 1.2 years as of September 30, 2023.

Table of Contents

NEWLAKE CAPITAL PARTNERS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2023

(Unaudited)

Note 9 - Stock Based Compensation (continued)

Performance Stock Units

Performance Stock Units (“PSUs”) are granted to officers and certain employees of the Company. Total outstanding PSUs as of September 30, 2023 and 2022 were 121,858 and 66,841, respectively.

The following table sets forth the Company's unvested performance stock activity for the nine months ended September 30,:


	For the Nine Months Ended September 30,
	2023			2022
	Number of Unvested Shares of PSUs	Weighted Average Grant Date Fair Value Per Share		Number of Unvested Shares of PSUs	Weighted Average Grant Date Fair Value Per Share
Balance at January 1,	66,841	$	24.04	77,742	$	24.04
Granted	55,017	$	11.23	—	$	—

Forfeited	—	—		(10,901)	$	24.03
Balance at September 30,	121,858	$	18.26	66,841	$	24.04

PSUs vest subject to the achievement of relative total shareholder return as measured against a peer group of companies and absolute compounded annual growth in stock price during each performance period. The actual number of shares of common stock issued will range from 0 to 243,716 depending upon performance. The performance periods are August 13, 2021 through December 31, 2023, January 1, 2022 through December 31, 2024, and January 1, 2023 through December 31, 2025 and 18,858, 47,983 and 55,017 PSUs are scheduled to vest at the end of each performance period, respectively.

PSUs are recorded at fair value which involved using a Monte Carlo simulation for the future stock prices of the Company and its corresponding peer group. A fair value of $24.15, $24.00 and $11.23 were used for PSUs with performance periods ending December 31, 2023, 2024 and 2025, respectively. PSUs are subject to restrictions on transfer and may be subject to a risk of forfeiture if the award recipient ceases to be an employee of the Company prior to vesting of the award.

Each PSU is entitled to receive a dividend equivalent payment equal to the dividend paid on the number of shares of common stock issued per PSU vesting. Unearned dividend equivalents on unvested PSUs as of September 30, 2023 and 2022 were $259,546 and $90,904, respectively.

The amortization of compensation costs for the awards of PSUs are included in "Compensation Expense" in the accompanying consolidated statements of operations and amounted to $0.6 million and $0.4 million for the nine months ended September 30, 2023 and 2022, respectively. The amortization of compensation costs for the awards of PSUs amounted to $0.2 million for both the three months ended September 30, 2023 and 2022. The remaining unrecognized compensation cost of approximately $1.0 million for PSU awards is expected to be recognized over a weighted average amortization period of 1.7 years as of September 30, 2023.

Stock Options

Prior to the completion of the IPO, the Company issued 791,790 nonqualified stock options (the “Options”) to purchase shares of the Company’s common stock, subject to the terms and conditions of the applicable Option Grant Agreements, with an exercise price per share of common stock equal to $24.00 and in such amounts as set forth in the Option Grant Agreements. The Options vested on August 31, 2020 and were fully exercisable as of September 30, 2023. The options expire on July 15, 2027.

Table of Contents

NEWLAKE CAPITAL PARTNERS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2023

(Unaudited)

Note 10 - Warrants

On March 17, 2021, in connection with the Merger, the Company entered into a warrant agreement which granted the right to purchase 602,392 shares of common stock of the Company at a purchase price of $24.00 per share. Warrants are immediately exercisable and expire on July 15, 2027.

The following table summarizes warrant activity for the nine months ended September 30,:


	2023			2022
	Number of Warrants(1)	Weighted Average Exercise Price		Number of Warrants(1)	Weighted Average Exercise Price
Exercisable at January 1,	602,392	$	24.00	602,392	$	24.00
Granted	—	—		—	—
Exercised	—	—		—	—
Exercisable at September 30,	602,392	$	24.00	602,392	$	24.00

(1) Warrants were granted on March 17, 2021.

Note 11 - Stockholders' Equity

Preferred Stock

As of September 30, 2023 and December 31, 2022, the Company had 100,000,000 shares of preferred stock authorized and 0 shares of preferred stock outstanding.

Common Stock

On August 13, 2021, the Company completed its initial public offering ("IPO") of 3,905,950 shares of common stock, with a par value $0.01 per share.

Stock Repurchase Program

On November 7, 2022, the board of directors of the Company authorized a stock repurchase program of its common stock up to $10.0 million through December 31, 2023. On September 15, 2023, the board of directors authorized an amendment to the stock repurchase program for the repurchase of up to an additional $10.0 million of outstanding common stock and extended the program through December 31, 2024. Purchases made pursuant to the stock repurchase program will be made in the open market, in privately negotiated transactions, or pursuant to any trading plan that may be adopted in accordance with Rule 10b-18 of the Securities and Exchange Act of 1934, as amended. The authorization of the stock repurchase program does not obligate the Company to acquire any particular amount of common stock. The timing, manner, price and amount of any repurchases will be determined by the Company in its discretion and will be subject to economic and market conditions, stock price, applicable

Table of Contents

NEWLAKE CAPITAL PARTNERS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2023

(Unaudited)

Note 11 - Stockholders' Equity (continued)

legal requirements and other factors. The stock repurchase program may be suspended or discontinued by us at any time and without prior notice.

For the nine months ended September 30, 2023, pursuant to the repurchase plan, the Company acquired 713,831 shares of common stock with an average price, including commissions, of $12.96 totaling approximately $9.3 million. The remaining availability under the program as of September 30, 2023 was approximately $10.7 million.

Conversion of OP Units

There were no OP Units converted to common stock during the nine or three months ended September 30, 2023. During the nine months ended September 30, 2022, 79,721 OP Units were converted one for one into shares of the Company's common stock. During the three months ended September 30, 2022, no OP Units were converted to common stock.

Dividends

The following tables describe the cash dividends, dividend equivalents on vested RSUs and, in the Company's capacity as general partner of the operating partnership, authorized distributions on the Company's OP Units declared by the Company during the nine months ended September 30, 2023 and 2022:

Declaration Date

Record Date

Period Covered

Distributions Paid Date

Amount per Share/Unit

March 7, 2023

March 31, 2023

January 1, 2023 to March 31, 2023

April 14, 2023

0.39

June 15, 2023

June 30, 2023

April 1, 2023 to June 30, 2023

July 14, 2023

0.39

September 15, 2023

September 29, 2023

July 1, 2023 to September 30, 2023

October 13, 2023

0.39

Total

1.17

Declaration Date

Record Date

Period Covered

Distributions Paid Date

Amount per Share/Unit

March 15, 2022

March 31, 2022

January 1, 2022 to March 31, 2022

April 14, 2022

0.33

June 15, 2022

June 30, 2022

April 1, 2022 to June 30, 2022

July 15, 2022

0.35

September 15, 2022

September 30, 2022

July 1, 2022 to September 30, 2022

October 14, 2022

0.37

Total

1.05

During the nine months ended September 30, 2023 and 2022, the Company paid $35,264 and $17,628, respectively, of dividend equivalents that became earned upon vesting of RSUs. During the three months ended September 30, 2023 and 2022, the Company paid $0 and $10,116, respectively, of dividend equivalents that became earned upon vesting of RSUs. There were no unearned dividends on PSUs that became earned during the three and nine months ended September 30, 2023 and 2022. The Company had unearned dividend equivalents on unvested RSUs and unvested PSUs of $348,302 and $126,754, as of September 30, 2023 and 2022, respectively.

Table of Contents

NEWLAKE CAPITAL PARTNERS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2023

(Unaudited)

Note 12 - Earnings Per Share

The following table presents the computation of basic and diluted earnings per share (in thousands, except share data):


	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2023		2022		2023		2022
Numerator:
Net Income Attributable to Common Stockholders	$	5,958	$	6,510	$	17,623	$	15,285

Add: Net Income Attributable to Noncontrolling Interest	108		113		312		262
Net Income	$	6,066	$	6,623	$	17,935	$	15,547

Denominator:
Weighted Average Shares of Common Stock Outstanding - Basic	21,199,638		21,428,905		21,330,046		21,417,149
Dilutive Effect of OP Units	373,582		373,582		373,582		398,614

Dilutive Effect of Unvested Restricted Stock Units	9,094		—		6,473		—
Weighted Average Shares of Common Stock - Diluted	21,582,314		21,802,487		21,710,101		21,815,763

Earnings Per Share - Basic
Net Income Attributable to Common Stockholders	$	0.28	$	0.30	$	0.83	$	0.71
Earnings Per Share - Diluted
Net Income Attributable to Common Stockholders	$	0.28	$	0.30	$	0.83	$	0.71

During the three and nine months ended September 30, 2023 and 2022, the effect of outstanding stock options and warrants were excluded in the Company's calculation of weighted average shares of common stock outstanding – diluted as their inclusion would have been anti-dilutive. During the three and nine months ended September 30, 2023, the effect of including outstanding unvested RSUs were included in the Company's calculation of weighted average shares of common stock outstanding - dilutive. During the three and nine months ended September 30, 2022, the effect of unvested RSUs were excluded in the Company's calculation of weighted average shares of common stock outstanding – diluted as their inclusion would have been anti-dilutive.

Note 13 – Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance also establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standards describe three levels of inputs that may be used to measure fair value:

Level 1 – Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2 – Includes other inputs that are directly or indirectly observable in the marketplace.

Table of Contents

NEWLAKE CAPITAL PARTNERS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2023

(Unaudited)

Note 13 – Fair Value Measurements (continued)

Level 3 – Unobservable inputs that are supported by little or no market activities, therefore requiring an entity to develop its own assumptions.

The following table presents the carrying value and estimated fair value of financial instruments at September 30, 2023 and December 31, 2022 (in thousands):


	September 30, 2023				December 31, 2022
	Carrying Value		Estimated Fair Value		Carrying Value		Estimated Fair Value
Note Receivable(1)	$	5,000	$	4,800	$	5,000	$	4,952
Revolving Credit Facility(2)	$	1,000	$	952	$	1,000	$	915
Seller Financing(2)	$	997	$	980	$	1,986	$	1,942

(1) The fair value measurement of the $5.0 million Note Receivable is based on unobservable inputs, and as such, is classified as Level III.

(2) The fair value measurement of the Company's Revolving Credit Facility and Seller Financing is based on observable inputs, and as such, is classified as Level II.

As of September 30, 2023 and December 31, 2022, the carrying amounts of financial instruments such as cash and cash equivalents, accounts payable and accrued expenses and other liabilities approximate their fair values due to their generally short-term nature and the market rates of interest of these instruments, and as such, are classified as Level I.

Note 14 - Commitments and Contingencies

As of September 30, 2023, the Company had aggregate unfunded commitments to invest $20.2 million to develop and improve its existing cultivation facilities in Arizona, Missouri, and Pennsylvania. Refer to Note 3 for further details on the Company's commitments.

The Company owns a portfolio of properties that it leases to entities which cultivate, harvest, process and distribute cannabis. Cannabis is an illegal substance under the Controlled Substances Act. Although the operations of the Company’s tenants are legalized in the states and local jurisdictions in which they operate, the Company and its tenants are subject to certain risks and uncertainties associated with conducting operations subject to conflicting federal, state and local laws in an industry with a complex regulatory environment which is continuously evolving. These risks and uncertainties include the risk that the strict enforcement of federal laws regarding cannabis would likely result in the Company’s inability, and the inability of its tenants, to execute their respective business plans.

Note 15 - Subsequent Events

Tenant Improvements

Subsequent to September 30, 2023, the Company funded approximately $2.9 million of tenant improvements for the expansion of the Company's cultivation facilities located in Arizona and Missouri.

Leases

Revolutionary Clinics

In October 2023, the Company entered into a lease amendment and forbearance agreement (the "Agreements”) for its existing lease agreement with Revolutionary Clinics on its cultivation facility in Massachusetts, where Revolutionary Clinics is the sole tenant. Under the terms of the Agreements, the lease term was extended by five

Table of Contents

NEWLAKE CAPITAL PARTNERS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2023

(Unaudited)

Note 15 - Subsequent Events (continued)

years. The Company received $480 thousand of unpaid rent and applied the remaining $315 thousand of security deposit; these amounts will be recognized as income in the fourth quarter of 2023. Additionally, the Company has received October and November contractual rent payments pursuant to the amended lease. The rental payments may escalate as the tenant’s business achieves certain gross revenue metrics. Under the forbearance agreement, the Company provided forbearance for approximately $2.0 million of back rental income. Lastly, the Company received 9.95% of equity in Revolutionary Clinics in the form of warrants.

Calypso

Calypso did not make its weekly October rent payments. However, it has resumed its weekly rent payments in November.

Disposition of Real Estate

In October 2023, the Company closed on the sale of its cultivation facility in Palmer, Massachusetts, for $2.0 million, which was leased to Mint. The Company's investment in the property was $1.9 million. Upon closing, Mint's lease agreement was terminated and they paid a portion of the closing costs, resulting in a break-even sale of the property.

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

SPECIAL NOTE REGARDING FORWARD LOOKING INFORMATION

NewLake Capital Partners, Inc. ("the Company," "we," "our," "us,") makes statements in this Quarterly Report on Form 10-Q (“Form 10-Q”) that are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In particular, statements pertaining to our capital resources, property performance, leasing rental rates, future dividends and results of operations contain forward-looking statements. Likewise, all of our statements regarding anticipated growth in our funds from operations, adjusted funds from operations, anticipated market conditions, demographics, and results of operations are forward-looking statements. You can identify forward-looking statements by the use of forward-looking terminology such as “believe,” “continue,” “could,” “expect,” “may,” “will,” “should,” “would,” “seek,” “approximately,” “intend,” “plan,” “pro forma,” “estimates,” “forecast,” “project,” or “anticipate” or the negative of these words and phrases or similar words or phrases which are predictions of or indicate future events or trends and which do not relate solely to historical matters. You can also identify forward-looking statements by discussions of strategy, plans or intentions.

Forward-looking statements involve numerous risks and uncertainties and you should not rely on them as predictions of future events. Forward-looking statements depend on assumptions, data or methods which may be incorrect or imprecise and we may not be able to realize them. We do not guarantee that the transactions and events described will happen as described (or that they will happen at all). The following factors, among others, could cause actual results and future events to differ materially from those set forth or contemplated in the forward-looking statements:

•actions and initiatives of the U.S. or state governments and changes to government policies and the execution and impact of these actions, initiatives and policies, including the fact that cannabis remains illegal under federal law;

•general economic conditions;

•adverse economic or real estate developments, either nationally or in the markets in which our properties are located;

•other factors affecting the real estate industry generally;

•increase in interest rates and operating costs;

•the impact of inflation;

•financial market fluctuations;

•the competitive environment in which we operate;

•the estimated growth in and evolving market dynamics of the regulated cannabis market;

•adverse economic effects on the cannabis market;

•the expected medical-use or adult-use cannabis legalization in certain states;

•shifts in public opinion regarding regulated cannabis;

•the additional risks that may be associated with certain of our tenants cultivating adult-use cannabis in our cultivation facilities;

•the risks associated with the development of cultivation centers and dispensaries;

•our ability to successfully identify opportunities in target markets;

•the lack of tenant security deposits will impact our ability to recover rents should our tenants default under their respective lease agreement;

Table of Contents

•our status as an emerging growth company and a smaller reporting company;

•our lack of an extensive operating history;

•the concentration of our tenants in certain geographical areas;

•our failure to generate sufficient cash flows to service any outstanding indebtedness;

•defaults on, early terminations of or non-renewal of leases by tenants, including significant tenants;

•our failure to acquire the properties in our identified pipeline successfully, on the anticipated timeline or at the anticipated costs;

•our failure to properly assess employment growth or other trends in target markets and other markets in which we seek to invest;

•lack or insufficient amounts of insurance;

•bankruptcy or insolvency of a significant tenant or a substantial number of smaller tenants;

•our access to certain financial resources, including banks and other financial institutions;

•reduced liquidity of our common stock resulting from limited availability of clearing firms that will settle our

securities offerings;

•our failure to successfully operate acquired properties;

•our ability to operate successfully as a public company;

•our dependence on key personnel and ability to identify, hire and retain qualified personnel in the future;

•conflicts of interests with our officers and/or directors stemming from their fiduciary duties to other entities, including our operating partnership;

•our failure to obtain necessary outside financing on favorable terms or at all;

•general volatility of the market price of our common stock;

•changes in GAAP;

•environmental uncertainties and risks related to adverse weather conditions and natural disasters;

•our failure to maintain our qualification as a REIT for federal income tax purposes;

•changes in governmental regulations or interpretations thereof, such as real estate and zoning laws and increases in real property tax rates and taxation of REITs; and

•the impact of COVID-19 pandemic, or future pandemics, on us, our business, our tenants, or the economy generally.

While forward-looking statements reflect our good faith beliefs, they are not guarantees of future performance. We disclaim any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, of new information, data or methods, future events or other changes after the date of this report, except as required by applicable law. You should not place undue reliance on any forward-looking statements that are based on information currently available to us or the third parties making the forward-looking statements.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and our audited consolidated financial statements and the related notes and the discussion under the heading

Table of Contents

"Management's Discussion and Analysis of Financial Condition and Results of Operations" for the fiscal year ended December 31, 2022 included in our most recent Annual Report on Form 10-K and our subsequent Quarterly Reports on Form 10-Q.

This discussion, particularly information with respect to our future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, includes forward-looking statements that involve risks and uncertainties as described under the heading "Special Note Regarding Forward-Looking Information" in this Quarterly Report on Form 10-Q. You should review the disclosure under the heading "Risk Factors" in our most recent annual report on Form 10-K for a discussion of important factors that could cause our actual results to differ materially from those anticipated in these forward-looking statements.

Overview

NewLake Capital Partners, Inc., ("the “Company,” "we," "our," "us,") is an internally managed REIT and a leading provider of real estate capital to state-licensed cannabis operators primarily through sale-leaseback transactions, third-party purchases and funding for build-to-suit projects. Our properties are leased to single tenants on a long-term, triple-net basis, which obligates the tenant for the ongoing expenses of the leased property, in addition to its rent obligations.

We were incorporated in Maryland on April 9, 2019. We conduct our business through a traditional umbrella partnership REIT structure, in which properties are owned by an operating partnership, directly or through subsidiaries. We are the sole general partner of our operating partnership and currently own approximately 98% of the OP Units. We have elected to be taxed as a REIT for U.S. federal income tax purposes beginning with our short taxable year ended December 31, 2019 and intend to operate our business so as to continue to qualify as a REIT.

Emerging Growth Company

We have elected to be an emerging growth company, as defined in the JOBS Act. An emerging growth company may take advantage of specified reduced reporting requirements and is relieved of certain other significant requirements that are otherwise generally applicable to public companies. As an emerging growth company, among other things:

•We are exempt from the requirement to obtain an attestation and report from our auditors on the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act;

•We are permitted to provide less extensive disclosure about our executive compensation arrangements; and

•We are not required to give our stockholders non-binding advisory votes on executive compensation or golden parachute arrangements.

We have elected to use an extended transition period for complying with new or revised accounting standards.

We may take advantage of the other provisions for up to five years or such earlier time that we are no longer an emerging growth company. We will cease to be an emerging growth company upon the earliest to occur of: (i) the last day of the first fiscal year in which our annual gross revenues exceed $1.2 billion, (ii) the date that we become a “large accelerated filer” as defined in Rule 12b-2 under the exchange, which would occur if the market value of our common stock that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter, or (iii) the date on which we have issued more than $1 billion in non-convertible debt during the preceding three-year period.

Factors Impacting Our Operating Results

Our results of operations are affected by a number of factors and depend on the rental revenue we receive from the properties that we own, interest income we receive from the loans we may originate, the timing of lease expirations, general market conditions, the regulatory environment in the cannabis industry, and the competitive environment for real estate assets that support the cannabis industry.

Table of Contents

Rental Revenues

We receive income from rental revenue generated from our real estate properties that we own and expect to acquire in the future. The amount of rental revenue depends upon a number of factors, including:

•Our ability to enter into new leases at market value rents inclusive of annual rent increases; and

•Rent collection, which primarily relates to each of our current and future tenant’s or guarantor’s financial condition and ability to make rent payments to us on time.

For the period ended September 30, 2023, all of our rental revenues were derived from triple-net leases to 13 tenants. Our leases obligate the tenant for all the ongoing expenses of a property, including real estate taxes, insurance, maintenance and utilities, in addition to its rent obligations and include a parent or other affiliate guarantee. Our revenues are, therefore, dependent on our tenants (and related guarantors) ability to meet their respective obligations to us. Our tenants operate in the regulated cannabis industry, which is an evolving and highly regulated space. Further, because the regulated cannabis industry is a relatively new space, some of our existing tenants have limited operating histories and may be more susceptible to payment and other lease defaults. Thus, our operating results will be significantly impacted by the ability of our tenants to achieve and sustain positive financial results.

Financial Performance and Condition of Our Tenants

We have 32 properties, including one that is held for sale, leased to 13 tenants. All of our tenants are performing under their lease agreement with the exception of one tenant discussed below.

We had one tenant, Revolutionary Clinics, Inc., who did not pay contractual rent for the nine months ended September 30, 2023. We held a security deposit of approximately three months of contractual rent, of which the Company applied $945 thousand towards the outstanding rent during the nine months ended September 30, 2023. Approximately $315 thousand of security deposit remains for future application. We will continue to assess and apply the remaining security deposit, as needed. We are currently in discussion with the tenant to negotiate a resolution, which could include rent deferrals, rent concessions or other concessions. Subsequent to September 30, 2023 we reached an agreement to restructure the existing lease agreement. Refer to Recent Development in Item 2 for details.

Market Conditions

Through the nine months ended September 30, 2023, financial markets were volatile in the first half of 2023, reflecting heightened geopolitical risks and material tightening of financial conditions since the U.S. Federal Reserve began increasing interest rates in the spring of 2022. The volatile financial markets have been subdued and lost steam during the quarter, with investors taking a risk-off stance. The tense regional banking crisis was short-lived as the banking system remains strong. Central banks continued to shrink their balance sheets during the quarter, reducing market liquidity. The inverted yield curve and tight monetary policy, have resulted in banks tightening their lending standards across multiple sectors, further reducing market liquidity. There continues to be uncertainty regarding monetary policy and inflation. With less than three months left in the year, most concerns about an economic recession have been pushed to 2024. While inflation is steadily trending downward, there are concerns that inflation may still prove stickier than the market anticipates, creating risks to corporate profit margins. Even though the Federal Reserve left rates unchanged in September, it has been signaling higher rates for longer as it continues to fight inflation, with borrowing costs at the highest level in 22 years. The increasing cost of capital is pressuring many U.S. corporations. U.S. corporate defaults have significantly increased in 2023 compared to 2022. These current market conditions have increased the cost of capital and reduced the availability of capital for us and our tenants.

Inflation and Supply Chain Constraints

Inflation continues to trend significantly higher than in prior periods, which may be negatively impacting some of our tenants. This inflation has impacted costs for labor and production inputs for regulated cannabis operators, in addition to increasing costs of construction for development and redevelopment projections. Ongoing labor shortages and global supply chain issues, geopolitical issues and the war in Ukraine, also continue to adversely impact costs and timing for

Table of Contents

completion of these development and redevelopment projects, which are resulting in cost overruns and delays in commencing operations on certain of our tenants' projects.

Competitive Environment

We face competition from a diverse mix of market participants, including but not limited to, other companies with similar business models, independent investors, hedge funds and other real estate investors, mortgage REITs, hard money lenders, as well as would-be tenants and cannabis operators themselves, all of whom may compete with us in our efforts to acquire real estate zoned for cannabis cultivation, production or dispensary operations. Competition from others may diminish our opportunities to acquire a desired property on favorable terms or at all. In addition, this competition may put pressure on us to reduce the rental rates below those that we expect to charge for the properties that we own and expect to acquire, which would adversely affect our financial results.

Critical Accounting Policies and Estimates

In accordance with generally accepted accounting principles in the United State of America, ("GAAP"), our consolidated financial statements require the use of estimates and assumptions that involve the exercise of judgment and use of assumptions. Our most critical accounting policies will involve decisions and assessments that could affect our reported assets and liabilities, as well as our reported revenues and expenses. Actual results could differ materially from those estimates and assumptions.

We believe that all of the decisions and assessments upon which our consolidated financial statements have been based were reasonable at the time made and based upon information available to us at that time. There have been no changes to the Company's critical accounting policies included in Note 2 to the Consolidated Financial Statements of the Company's Annual Report on Form 10-K for the year ended December 31, 2022, except as follows:

Property Held for Sale

We classify real estate held for sale when the following criteria are met: (i) management commits to a plan to sell the property, (ii) the property is available for sale, (iii) the property is actively being marketed for sale at a price that is reasonable, (iv) the sale of the property within one year is considered probable, and (iv) significant change to the plan to sell the property is not expected. A real estate asset held for sale is classified as "Property Held for Sale" in the consolidated balance sheets. A property classified as held for sale is no longer depreciated and is required to be reported at the lower of its carrying value or its fair value less cost to sell.

Financial Instruments - Credit Losses

We adopted ASC 326, Financial Instruments - Credit Losses ("CECL") on January 1, 2023, which did not have a material impact to our financial statements. The CECL expected loss model requires an allowance for all expected credit losses for the life of a loan be recognized when the loan is either originated or acquired. The allowance for credit losses is a valuation account that is deducted from, or added to, the amortized cost basis of the financial asset(s) to present the net amount expected to be collected on the financial asset(s). At each reporting period, the company will update its estimate and adjust the allowance for credit losses accordingly. Increases in the allowance are recorded through net income as credit loss expense. Decreases in the allowance are recorded through net income as a reversal of credit loss expense. This standard does not specify a specific measurement technique for estimating expected credit losses. Approaches can vary based on a variety of factors. We generally use a discounted cash flow model approach to determine the credit loss, if any, for its financial instruments subject to the CECL guidance.

Q3 2023 Highlights

Investment Activity

Real Estate Acquisitions

As of September 30, 2023, we owned a geographically diversified portfolio consisting of 32 properties, including one property held for sale, across 12 states with 13 tenants, comprised of 17 dispensaries and 15 cultivation facilities with a weighted average remaining lease term of 14.2 years. All of our leases, and the secured loan, include a parent or other affiliate guarantee.

Table of Contents

The following table presents our investment activity for the nine months ended September 30, 2023 (in thousands):

Tenant

Market

Site Type

Closing Date

Real Estate Acquisition Costs

Bloom Medicinal

Missouri

Cultivation

March 3, 2023

350

(1)

Total

350

(1) The Company exercised its option to purchase the adjacent parcel of land to expand our cultivation facility in Missouri and has committed to fund $16.2 million for the expansion.

The following table presents the tenant improvements funded during the nine months ended September 30, 2023 (in thousands):

Tenant

Market

Site Type

Acquisition Closing Date

Tenant Improvements Funded

Unfunded Commitments

Mint

Arizona

Cultivation

June 24, 2021

2,366

5,703

(1)

Organic Remedies

Missouri

Cultivation

December 20, 2021

282

—

Bloom Medicinal

Missouri

Cultivation

April 1, 2022

2,961

13,722

Ayr Wellness, Inc.

Pennsylvania

Cultivation

June 30, 2022

—

750

Total

5,609

20,175

(1)The tenant had been paying rent on approximately $1.6 million of the TI funded since July 2022 in accordance with the lease agreement. Effective June 1, 2023, the lease agreement was amended to include an additional TI commitment of approximately $6.5 million.

Held for Sale Real Estate

On August 25, 2023, we entered into a purchase and sale agreement for the sale of our Massachusetts property that is leased to Mint, subject to customary buyer's due diligence. In connection with the agreement, the buyer deposited $100,000 into an escrow account. The escrow deposit was fully refundable if the contract was terminated during the due diligence period. As of September 30, 2023, the due diligence period had expired and $75,000 of the escrow deposit became non-refundable in the event the buyer terminated the contract. The escrow deposit was not recorded in the accompanying consolidated balance sheet as of September 30, 2023. The sale closed subsequent to September 30, 2023 refer Recent Development in Item 2 for additional information.

Financing Activity

Seller Financing

In January 2023, we made our annual principal payment of $1.0 million. The loan's outstanding balance as of September 30, 2023 was $1.0 million and the remaining unamortized discount was $3.4 thousand. The final principal payment is due in January 2024.

Revolving Credit Facility

The outstanding borrowings under the Revolving Credit Facility were $1.0 million as September 30, 2023. Refer to Note 6 in the Notes to Consolidated Financial Statements in Part I – Item 1 for further information.

Capital Markets Activity

Stock Repurchase Program

On November 7, 2022, our board of directors approved a repurchase program of up to $10.0 million of our common stock through December 31, 2023. On September 15, 2023, our board of directors authorized an amendment to the stock repurchase program for the repurchase of up to an additional $10.0 million of our outstanding common stock and extended the program through December 31, 2024. During the nine months ended September 30, 2023, pursuant to the repurchase

Table of Contents

plan, we acquired 713,831 shares of common stock with an average price, including commissions, of $12.96, totaling approximately $9.3 million.

Recent Developments

Tenant Improvements

We funded approximately $2.9 million of tenant improvements for the expansion of our cultivation facilities located in Arizona and Missouri subsequent to quarter end.

Leases

Revolutionary Clinics

In October 2023, we entered into a lease amendment and forbearance agreement (the “Agreements”) for our existing lease agreement with Revolutionary Clinics on our cultivation facility in Massachusetts, where Revolutionary Clinics is the sole tenant. Under the terms of the Agreements, the lease term was extended by five years. We received $480 thousand of unpaid rent and applied the remaining $315 thousand of security deposit; these amounts will be recognized as income in the fourth quarter of 2023. Additionally, we received October and November contractual rent payments pursuant to the amended lease. The new reduced rental payments are expected to represent approximately 6.1% of our estimated fourth quarter 2023 portfolio contractual rental income. The rental payments may escalate as the tenant’s business achieves certain gross revenue metrics. Under the Agreements, we provided forbearance for approximately $2.0 million of back rental income. Lastly, we received 9.95% of equity in Revolutionary Clinics in the form of warrants.

Calypso

Calypso did not make their weekly October rent payments. However, they resumed their weekly rent payments in November. Calypso continues to work towards a sale of its business.

Disposition of Real Estate

In October 2023, we closed on the sale of our cultivation facility in Palmer, Massachusetts, for $2.0 million, which was leased to Mint. Our investment in the property was approximately $1.9 million. Upon closing, Mint's lease agreement was terminated and they paid a portion of the closing costs, resulting in a break-even sale of the property.

Results of Operations

General

We derive substantially all our revenue from rents received from single tenants of each of our properties under triple-net leases. Our triple-net leases obligate the tenant for all the ongoing expenses of a property, including real estate taxes, insurance, maintenance and utilities, in addition to its rent obligations. Our leases also typically include annual rent escalations (typically within the range of 2-3%) as a set percentage or based on an inflation index, which generally provides us with contractual revenue growth and inflation-protected returns. All of our leases include a parent or other affiliate guarantee.

Table of Contents

Comparison of the three months ended September 30, 2023 and 2022 (in thousands):


	For the Three Months Ended September 30,				Increase/(Decrease)
	2023		2022		Q3'23 vs Q3'22
Revenue:
Rental Income	$	11,297	$	11,595	$	(298)
Interest Income from Loans	131		434		(303)
Fees and Reimbursables	63		49		14
Total Revenue	11,491		12,078		(587)

Expenses:
Depreciation and Amortization Expense	3,568		3,630		(62)


General and Administrative Expenses:
Compensation Expense	1,173		1,040		133
Professional Fees	300		279		21
Other General and Administrative Expenses	467		419		48
Total General and Administrative Expenses	1,940		1,738		202

Total Expenses	5,508		5,368		140



Income From Operations	5,983		6,710		(727)

Other Income (Expenses):
Interest Income	178		7		171
Interest Expense	(95)		(94)		(1)
Total Other Income (Expense)	83		(87)		170

Net Income	6,066		6,623		(557)



Net Income Attributable to Noncontrolling Interests	(108)		(113)		5

Net Income Attributable to Common Stockholders	$	5,958	$	6,510	$	(552)

Revenues

Rental Income

Rental income for the three months ended September 30, 2023 decreased by approximately $0.3 million to approximately $11.3 million, compared to approximately $11.6 million for the three months ended September 30, 2022. The decrease in rental income was mainly attributable to one non-performing tenant, Revolutionary Clinics, that failed to pay contractual rent of approximately $1.3 million for three months ended September 30, 2023. We applied 25% or $315 thousand of the security deposit towards the outstanding rent. In October, we entered into a lease amendment and forbearance agreement with Revolutionary Clinics. Refer to Recent Development in Item 2 of this Form 10-Q for details. Also, to a lesser extent the sale of one of our properties in Massachusetts during 2022 contributed to the decrease in rental income.

The decrease was partially offset by increases in rental income from the following;

•A full quarter of rental income from a cultivation facility that converted from a mortgage loan to a 20 year sale-leaseback on August 5, 2022. The increase also includes a full quarter of rental income from

Table of Contents

exercising our option to acquire the adjacent land parcel to expand one of our existing cultivation facility in Missouri during the first quarter of 2023. These acquisitions generated approximately $0.3 million of rental income during the three months ended September 30, 2023.

•Funding of tenant improvements at our Arizona and Missouri cultivation facilities which generated approximately $0.1 million of additional rental income during the three months ended September 30, 2023.

•Annual escalations on our portfolio generated an increase of approximately $0.2 million of rental revenue during the three months ended September 30, 2023.

Interest Income from Loans

Interest income from loans decreased by approximately $0.3 million for the three months ended September 30, 2023 compared to the three months ended September 30, 2022. The decrease of approximately $0.3 million was attributable to the conversion of the $30.0 million mortgage loan we entered into during the fourth quarter of 2021 that converted to a 20 year sale-leaseback, in accordance with the loan agreement, on August 5, 2022.

Expenses

Depreciation and Amortization Expense

Depreciation and amortization expense was relatively flat quarter over quarter.

General and Administrative Expense

Total general and administrative expenses for the three months ended September 30, 2023 increased by approximately $0.2 million, to $1.9 million, compared to $1.7 million for the three months ended September 30, 2022. The increase in general and administrative expense is described below by category.

Compensation Expense

Compensation expense includes compensation to employees and officers of the Company and stock-based compensation awards. Compensation expense increased by approximately $0.1 million for the three months ended September 30, 2023 compared to the three months ended September 30, 2022. The increase was attributable to a full quarter of compensation expense for two new hires in the second and third quarters of 2022 and an increase in stock based compensation from 2023 RSU and PSU grants. The increase was partially offset by one-time severance payments related to the retirement and separation of certain executive officers during 2022.

Professional Fees

Professional fees were relatively flat quarter over quarter.

Other General and Administrative Expenses

Other general and administrative expense was relatively flat quarter over quarter.

Other Income (Expense)

Interest income increased during the three months ended September 30, 2023 by approximately $171 thousand, to $178 thousand compared to $7 thousand for the three months ended September 30, 2022, primarily due to higher interest rates on our cash balances in our money market accounts.

Interest expense remained relatively flat quarter over quarter.

Table of Contents

Comparison of the nine months ended September 30, 2023 and 2022 (in thousands):


	For the Nine Months Ended September 30,			Increase/(Decrease)
		2023		2022		Q3'23 vs Q3'22
Revenue:
Rental Income		$	33,637	$	30,217	$	3,420
Interest Income from Loans		390		2,301		(1,911)
Fees and Reimbursables		256		239		17
Total Revenue		34,283		32,757		1,526

Expenses:
Depreciation and Amortization Expense		10,698		9,113		1,585


General and Administrative Expenses:
Compensation Expense		3,450		5,100		(1,650)
Professional Fees		986		1,486		(500)
Other General and Administrative Expenses		1,537		1,387		150
Total General and Administrative Expenses		5,973		7,973		(2,000)

Total Expenses		16,671		17,086		(415)

Loss on Sale of Real Estate		—		(60)		60

Income From Operations		17,612		15,611		2,001

Other Income (Expenses):
Interest Income		607		103		504
Interest Expense		(284)		(167)		(117)
Total Other Income (Expense)		323		(64)		387

Net Income		17,935		15,547		2,388



Net Income Attributable to Noncontrolling Interests		(312)		(262)		(50)
Net Income Attributable to Common Stockholders		$	17,623	$	15,285	$	2,338

Revenues

Rental Income

Rental income for the nine months ended September 30, 2023 increased by approximately $3.4 million to approximately $33.6 million, compared to approximately $30.2 million for the nine months ended September 30, 2022. The increase in rental income was primarily attributable to:

•A full nine months of rental income from two cultivation facilities acquired at the end of the second quarter of 2022 and one cultivation facility that converted from a mortgage loan to a 20 year sale-leaseback in August of 2022. The increase also includes a full six months of rental income from exercising our option to acquire the adjacent land parcel to expand one of our existing cultivation facilities in Missouri during the first quarter of 2023. These acquisitions generated approximately $3.6 million of rental income during the nine months ended September 30, 2023.

Table of Contents

•Funding of tenant improvements at our Arizona, Florida and both Missouri cultivation facilities which generated approximately $2.1 million of additional rental income during the nine months ended September 30, 2023.

•Annual escalations on our portfolio generated an increase of approximately $0.5 million of rental revenue during the nine months ended September 30, 2023.

The increase in rental revenue was partially offset by a decrease of approximately $2.9 million in rental income attributable to one non-performing tenant Revolutionary Clinics, that failed to pay contractual rent under its lease agreement. During the nine months ended September 30, 2023, this tenant did not pay approximately $3.9 million of contractual rent to which we applied $945 thousand of their security deposit towards the outstanding rent. As of September 30, 2023, $315 thousand of the original security deposit remains available to be applied in future periods if needed. In October, we entered into a lease amendment and forbearance agreement with Revolutionary Clinics. Refer to Recent Development in Item 2 of this Form 10-Q for details. Also, to a lesser extent the sale of one of our properties in Massachusetts during 2022 contributed to the partial offset in the increase in rental income.

Interest Income from Loans

Interest income from loans decreased by approximately $1.9 million for the nine months ended September 30, 2023 compared to the nine months ended September 30, 2022. Approximately $2.1 million of the decrease was attributable to the conversion of the $30.0 million mortgage loan we entered into during the fourth quarter of 2021 that converted to a 20 year sale-leaseback, in accordance with the loan agreement, on August 5, 2022. The decrease was offset by an increase of approximately $0.2 million of interest income in connection with a $5.0 million unsecured loan that was originated on June 10, 2022, in connection with the purchase of a Missouri cultivation facility.

Expenses

Depreciation and Amortization Expense

Depreciation and amortization expense for the nine months ended September 30, 2023 increased by approximately $1.6 million to approximately $10.7 million compared to approximately $9.1 million for the nine months ended September 30, 2022. The increase in depreciation was attributable to: (i) the acquisition of three cultivation facilities and one dispensary acquired during 2022; (ii) the mortgage loan that converted to a twenty year sale-leaseback property on August 5, 2022; (iii) the expansion at an existing cultivation facility in Florida; and (iv) approximately $30.7 million of improvements that were placed into service during 2022 and subsequent.

General and Administrative Expense

Total general and administrative expenses for the nine months ended September 30, 2023 decreased by approximately $2.0 million, to $6.0 million, compared to $8.0 million for the nine months ended September 30, 2022. The decrease in general and administrative expense is described below by category.

Compensation Expense

Compensation expense includes compensation to employees and officers of the Company and stock-based compensation awards. Compensation expense decreased by approximately $1.7 million during the nine months ended September 30, 2023 compared to nine months ended September 30, 2022. The decrease was primarily due to one-time severance payments of approximately $1.7 million from the retirement and separation of certain executive officers of the Company during the nine months ended September 30, 2023 and a decrease in stock-based compensation of approximately $0.2 million primarily due to the accelerated expense on RSUs related to the retirement and separation of certain executive officers. These decreases were partially offset by an increase in compensation expense due to new hires during 2022.

Professional Fees

Professional fees for the nine months ended September 30, 2023, decreased by approximately $500 thousand to approximately $986 thousand, compared to approximately $1.5 million for the nine months ended September 30, 2022. The decrease was mainly attributable to the reduction of approximately $115 thousand related to the elimination of outsourced accounting functions, a decrease of approximately $181 thousand in recruiting fees not incurred during 2023, a

Table of Contents

decrease of approximately $80 thousand in consulting fees and a decline of approximately $168 thousand in legal fees associated with a potential restructuring. These decreases were offset by an increase in general legal and tax preparation fees.

Other General and Administrative Expenses

For the nine months ended September 30, 2023, other general and administrative expenses increased by approximately $150 thousand to approximately $1.5 million, compared to $1.4 million for the nine months ended September 30, 2022. Other general and administrative expenses is comprised of director and officer insurance, information technology, public relations fees, filing and regulatory fees and various other expenses. The increase was mainly attributable to higher reporting costs, public relations fees, information technology costs and corporate rent, offset by lower director and officer insurance costs.

Loss on Sale of Real Estate

The Company did not sell any properties during the nine months ended September 30, 2023.

On March 21, 2022, we sold our PharmaCann Massachusetts property for approximately $800 thousand. We recognized a loss on sale of the property of $60 thousand during the nine months ended September 30, 2022.

Other Income (Expense)

Interest income increased during the nine months ended September 30, 2023 by approximately $504 thousand, to $607 thousand compared to $103 thousand for the nine months ended September 30, 2022, primarily due to higher interest rates on our cash balances in our money market accounts.

Interest expense increased during the nine months ended September 30, 2023 by approximately $117 thousand to approximately $284 thousand, compared to $167 thousand for the nine months ended September 30, 2022. The increase was mainly attributable to a full nine months of interest expense on the draw of $1.0 million from the Revolving Credit Facility we entered into on May 6, 2022, and the associated non-cash interest expense which increased by approximately $181 thousand related to the amortization of deferred financing costs incurred in connection with this facility. The increase was partially offset by a decrease in interest expense on our loan payable in connection with the $1.0 million principal pay down in January 2023.

Non-GAAP Financial Information and Other Metrics

Funds from Operations and Adjusted Funds from Operations

FFO and AFFO are non-GAAP financial measures and should not be viewed as alternatives to net income calculated in accordance with GAAP as a measurement of our operating performance. We believe that FFO and AFFO are useful to investors because they are widely accepted industry measures used by analysts and investors to compare the operating performance of REITs.

We calculate FFO in accordance with the current National Association of Real Estate Investment Trusts (“NAREIT”) definition. NAREIT currently defines FFO as follows: net income (loss) (computed in accordance with GAAP) excluding depreciation and amortization related to real estate, gains and losses from the sale of certain real estate assets, and impairment write-downs of certain real estate assets and investments in entities when the impairment is directly attributable to decreases in the value of depreciable real estate held by an entity. Other REITs may not define FFO in accordance with the NAREIT definition or may interpret the current NAREIT definition differently than we do and therefore our computation of FFO may not be comparable to such other REITs.

We calculate AFFO by starting with FFO and adding back non-cash and certain non-recurring transactions, including non-cash components of compensation expense and our internalization costs. Other REITs may not define AFFO in the same manner as we do and therefore our calculation of AFFO may not be comparable to such other REITs. You should not consider FFO and AFFO to be alternatives to net income as a reliable measure of our operating performance; nor should you consider FFO and AFFO to be alternatives to cash flows from operating, investing or financing activities (as defined by GAAP) as measures of liquidity.

Table of Contents

The table below is a reconciliation of net income attributable to common stockholders to FFO and AFFO for the three and nine months ended September 30, 2023 and 2022 (in thousands):


	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2023		2022		2023		2022
Net Income Attributable to Common Stockholders	$	5,958	$	6,510	$	17,623	$	15,285
Net Income Attributable to Noncontrolling Interests	108		113		312		262
Net Income	6,066		6,623		17,935		15,547

Adjustments:
Real Estate Depreciation and Amortization	3,568		3,630		10,698		9,113
Loss on Sale of Real Estate	—		—		—		60
FFO Attributable to Common Stockholders - Diluted (1)	9,634		10,253		28,633		24,720
Severance	—		25		—		1,752
Stock-Based Compensation	379		280		1,060		1,201
Non-cash Interest Expense	71		59		211		92
Amortization of Straight-line Rent Expense	—		6		—		12
AFFO Attributable to Common Stockholders - Diluted	$	10,084	$	10,623	$	29,904	$	27,777

Liquidity and Capital Resources

Our cash requirements include the payment of dividends, to our shareholders, distributions to our OP Unit holders, general and administrative expenses, debt service, other expenses related to managing our existing portfolio as well as acquisition and unfunded tenant improvement costs. The sources of liquidity to fund these cash requirements include rental revenue from the leasing of our properties, which is our primary source of cash flow, borrowings under our revolving credit facility and equity and debt issuances either in the public or private markets, if markets permit. Where possible, we also may issue OP Units to acquire properties from existing owners seeking a tax-deferred transaction.

As of September 30, 2023, we had $120.1 million of liquidity comprised of $31.1 million of cash and cash equivalents and $89.0 million available on our $90.0 million revolving credit facility, subject to sufficient collateral in the borrowing base. The ongoing challenges posed by the increase in interest rates and inflation could adversely impact our cash flow from continuing operations but we expect that cash flow from continuing operations over the next twelve months, together with cash on hand, will be adequate to fund our business operations, cash dividends to our shareholders, distributions to our OP Unit holders and debt service. Acquisitions and unfunded tenant improvement costs may require funding from borrowings, equity issuance and/or issuance of OP units. We cannot, however, be certain that these sources of funds will be available at a time and upon terms acceptable to us in sufficient amounts in the future.

Summary of Cash Flows

The following summary discussion of our cash flows is based on the consolidated statements of cash flows in our consolidated financial statements and is not meant to be an all-inclusive discussion of the changes in our cash flows for the periods presented below (in thousands):


	For the Nine Months Ended September 30,
	2023		2022
Net Cash Provided by Operating Activities	$	27,603	$	23,524
Net Cash Used in Investing Activities	$	(5,959)	$	(83,176)
Net Cash Used in Financing Activities	$	(35,771)	$	(22,422)
Cash and Cash Equivalents - End of Period	$	31,065	$	45,023

Table of Contents

Net Cash Provided by Operating Activities:

Net cash provided by operating activities for the nine months ended September 30, 2023 and 2022 were approximately $27.6 million and $23.5 million, respectively. Net cash flows provided by operating activities for the nine months ended September 30, 2023 and 2022 were primarily related to contractual rent and security deposits received from our properties, partially offset by our general and administrative expenses.

Net Cash Used in Investing Activities:

Net cash used in investing activities for the nine months ended September 30, 2023 and the nine months ended September 30, 2022 were approximately $6.0 million and $83.2 million, respectively. Cash used in investing activities for the nine months ended September 30, 2023 related to approximately $350 thousand used to purchase an adjacent parcel of land by an existing cultivation facility in Missouri and approximately $5.6 million used to fund tenant improvements. Net cash used in investing activities for the nine months ended September 30, 2022 related to approximately $35.4 million used to purchase three cultivation facilities, approximately $43.5 million used to fund tenant improvements and $5.0 million used to fund an unsecured loan receivable at our cultivation facility in Missouri, partially offset by approximately $0.8 million of proceeds received from sale of our Franklin, Massachusetts property.

Net Cash Used in Financing Activities:

Net cash used in financing activities for the nine months ended September 30, 2023 and the nine months ended September 30, 2022 were approximately $35.8 million and $22.4 million, respectively. Cash used in financing activities for the nine months ended September 30, 2023, related to approximately $25.5 million in dividend payments to holders of our common stock, as well as distributions to OP Units and RSU holders, $1.0 million to pay down our loan payable, approximately $9.3 million to buy back stock under the stock repurchase program and approximately $28 thousand in deferred financing costs related to obtaining our Revolving Credit Facility. Net cash used in financing activities for the nine months ended September 30, 2022, were related to approximately $21.6 million in dividend payments to holders of our common stock, as well as distributions to OP Units and RSU holders and $1.8 million to pay down our loan payable, offset by $1.0 million drawn on our revolving credit facility.

Dividends

To maintain our qualification as a REIT, U.S. federal income tax law generally requires that we distribute at least 90% of our REIT taxable income annually, determined without regard to the deduction for dividends paid and excluding capital gains. We must pay tax at regular corporate rates to the extent that we annually distribute less than 100% of our taxable income. We evaluate each quarter to determine our ability to pay dividends to our stockholders based on our net taxable income if and to the extent authorized by our board of directors. Before we pay any dividend, whether for U.S. federal income tax purposes or otherwise, we must first meet both our operating requirements and debt service payments. If our cash available for distribution is less than our net taxable income, we could be required to sell assets or borrow funds to make cash distributions or we may make a portion of the required distribution in the form of a taxable stock distribution.

As a result of this distribution requirement, our Operating Partnership cannot rely on retained earnings to fund its ongoing operations to the same extent that other companies whose parent companies are not REITs can. During the nine months ended September 30, 2023, we declared, and our board of directors approved, cash dividends on our common stock and restricted stock units and in our capacity as general partner of the Operating Partnership, authorized distributions on our OP Units totaling approximately $25.2 million. During the nine months ended September 30, 2022, we declared, and our board of directors approved, cash dividends on our common stock and restricted stock units and in our capacity as general partner of the Operating Partnership, authorized distributions on our OP Units totaling approximately $22.9 million.

Contractual Obligations and Commitments

Unfunded Commitments

As of September 30, 2023, the Company had aggregate unfunded commitments of $20.2 million to develop and improve our existing cultivation facilities in Arizona, Missouri, and Pennsylvania.

Table of Contents

Corporate Office Lease

As of September 30, 2023, the Company is the lessee under one office lease for a term of four years, subject to annual escalations. The annual rent payments range from approximately $72 thousand in year one to approximately $85 thousand in year four. The office lease has a remaining weighted average term of approximately 2.9 years.

Revolving Credit Facility

As of September 30, 2023, the Company had $1.0 million drawn on our Revolving Credit Facility which bears interest at a rate of 5.65% per annum.

Adoption of New or Revised Accounting Standards

We are an emerging growth company, as defined in the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.

Interest Rate Risk

Interest rates are highly sensitive to many factors, including fiscal and monetary policies and domestic and international economic and political considerations, as well as other factors beyond our control. We are subject to interest rate risk in connection with our Revolving Credit Facility. As of September 30, 2023, we had $1.0 million principal drawn on our Revolving Credit Facility, at a fixed interest rate of 5.65% through May 2025 and a floating rate thereafter. Therefore, if interest rates decrease, our required interest payments may exceed those based on current market rates. If interest rates remain higher for longer, our cost of financing will significantly increase when the Revolving Credit facility adjusts to a floating rate subsequent to May 2025.

Impact of Inflation

The U.S. economy has experienced an increase in inflation rates recently. We enter into leases that generally provide for annual fixed increases in rent at a fixed rate. In some instances, leases provide for annual increases in rent based on the increase in annual CPI. We expect these lease provisions to result in rent increases over time. During times when inflation is greater than increases in rent, as provided for in the leases, rent increases may not keep up with the rate of inflation.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

In the commercial real estate market, property prices generally continue to fluctuate. Likewise, during certain periods, the U.S. credit markets have experienced significant price volatility, dislocations, and liquidity disruptions, which may impact our access to and cost of capital. We continually monitor the commercial real estate and U.S. credit markets carefully and, if required, will make decisions to adjust our business strategy accordingly.

ITEM 4. CONTROLS AND PROCEDURES.

Our management, including our Chief Executive Officer (the CEO) and Chief Financial Officer (the CFO), reviewed and evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act) as of the end of the period covered by this report. Based on that review and evaluation, the CEO and CFO have concluded that our current disclosure controls and procedures, as designed, (1) were effective in ensuring that information required to be disclosed by the Company in reports it files or submits under the Securities Exchange Act is accumulated and communicated to our management, including our CEO and CFO, as appropriate to allow timely decisions regarding required disclosure and (2) were effective in ensuring that information required to be disclosed by the Company in reports it files or submits under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified by the SEC’s rules and forms.

Table of Contents

Limitations on Controls

Our system of internal control over financial reporting was designed to provide reasonable assurance regarding the preparation and fair presentation of published financial statements in accordance with accounting principles generally accepted in the United States. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance and may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal controls over financial reporting that occurred during the three months ended September 30, 2023 that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

Table of Contents

PART II — OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

We are not currently a party to any material legal proceedings. From time to time, we may in the future be a party to various claims and routine litigation arising in the ordinary course of business.

ITEM 1A. RISK FACTORS

There have been no material changes to the risk factors set forth in the section titled “Risk Factors” included in our Annual Report on Form 10-K, dated March 9, 2023, filed with the SEC. Our business involves significant risks. You should carefully consider the risks and uncertainties described in our Annual Report on Form 10-K, together with all of the other information in this Quarterly Report on Form 10-Q, as well as our audited consolidated financial statements and related notes as disclosed in our Annual Report. The risks and uncertainties described in our Annual Report are not the only ones we face. Additional risk and uncertainties that we are unaware of or that we deem immaterial may also become important factors that adversely affect our business. The realization of any of these risks and uncertainties could have a material adverse effect on our reputation, business, financial condition, results of operations, growth and future prospects as well as our ability to accomplish our strategic objectives. In that event, the market price of our common stock could decline and you could lose part or all of your investment.

Table of Contents

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND ISSUER PURCHASE OF EQUITY SECURITIES.

On November 7, 2022, our board of directors authorized a common stock repurchase program, to repurchase up to $10.0 million of our outstanding common stock (the “Repurchase Program”). Such authorization has an expiration date of December 31, 2023. On September 15, 2023, the board of directors authorized an amendment to the stock repurchase program for the repurchase of up to an additional $10.0 million of its outstanding common stock and extended the program through December 31, 2024. The purchases totaling 713,831 shares of common stock with an average price, including commissions, of $12.96 for approximately $9.3 million were made in the open market in accordance with Rule 10b-18 of the Securities and Exchange Act of 1934. The remaining availability under the program as of September 30, 2023 was approximately $10.7 million.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

Not applicable.

ITEM 4. MINE SAFETY DISCLOSURE.

Not applicable.

ITEM 5. OTHER INFORMATION.

During the three months ended September 30, 2023, none of the Company's directors or officers adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K of the Securities Act of 1933).

ITEM 6. EXHIBITS.

EXHIBIT INDEX


Exhibit Number						Description
3.1						Articles of Amendment and Restatement of NewLake Capital Partners, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant's Registration Statement on Form S-11 filed on June 21, 2021).
3.2						Articles Supplementary of NewLake Capital Partners, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on September 19, 2022).
3.3						Amended and Restated Bylaws of NewLake Capital Partners, Inc. (incorporated by reference to Exhibit 3.3 to the Registrant's Quarterly Report on Form 10-Q filed on November 10, 2022).
31.1*						Certification of the Chief Executive Officer under Section 302 of the Sarbanes-OxleyAct of 2002.
31.2*						Certification of the Chief Financial Officer under Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*						Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*						Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*						Inline XBRL Instance Document.
101.SCH*						Inline XBRL Taxonomy Extension Schema Document.
101.CAL*						Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*						Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*						Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*						Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104						Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).

_______________________

†Management contracts or compensatory plans required to be filed as Exhibits to this Form 10-Q.

Table of Contents

*Filed herewith.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	NEWLAKE CAPITAL PARTNERS, INC.

Dated: November 9, 2023	By:	/s/ Anthony Coniglio
		Name: Anthony Coniglio
		Title: President and Chief Executive Officer
		(Principal Executive Officer)

Dated: November 9, 2023	By:	/s/ Lisa Meyer
		Name: Lisa Meyer
		Title: Chief Financial Officer, Treasurer and Secretary
		(Principal Financial Officer and Principal Accounting Officer)

Exhibit 31.1

CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES

EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

I, Anthony Coniglio, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of NewLake Capital Partners, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: November 9, 2023	By:	/s/ Anthony Coniglio
		Anthony Coniglio
		President and Chief Executive Officer
		(Principal Executive Officer)

Exhibit 31.2

CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES

EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

I, Lisa Meyer, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of NewLake Capital Partners, Inc.;

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: November 9, 2023	By:	/s/ Lisa Meyer
		Lisa Meyer
		Chief Financial Officer, Treasurer and Secretary
		(Principal Financial Officer)

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of NewLake Capital Partners, Inc. (the “Company”) for the quarter ended September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Anthony Coniglio, President and Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

(1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

It is not intended that this statement be deemed to be filed for purposes of the Securities Exchange Act of 1934.


Date: November 9, 2023	By:	/s/ANTHONY CONIGLIO
		Anthony Coniglio
		President and Chief Executive Officer
		(Principal Executive Officer)

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of NewLake Capital Partners, Inc. (the “Company”) for the quarter ended September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Lisa Meyer, Chief Financial Officer, Treasurer and Secretary of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

(1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

It is not intended that this statement be deemed to be filed for purposes of the Securities Exchange Act of 1934.


Date: November 9, 2023	By:	/s/ Lisa Meyer
		Lisa Meyer
		Chief Financial Officer, Treasurer and Secretary
		(Principal Financial Officer)

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2023	Nov. 07, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Document Transition Report	false
Entity File Number	000-56327
Entity Registrant Name	NewLake Capital Partners, Inc.
Entity Incorporation, State or Country Code	MD
Entity Tax Identification Number	83-4400045
Entity Address, Address Line One	50 Locust Avenue, First Floor
Entity Address, City or Town	New Canaan
Entity Address, State or Province	CT
Entity Address, Postal Zip Code	06840
City Area Code	203
Local Phone Number	594-1402
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		20,694,363
Entity Central Index Key	0001854964
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Amendment Flag	false

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Real Estate
Land	$ 21,397	$ 21,427
Building and Improvements	382,087	378,047
Total Real Estate	403,484	399,474
Less Accumulated Depreciation	(28,931)	(19,736)
Net Real Estate	374,553	379,738
Cash and Cash Equivalents	31,065	45,192
In-Place Lease Intangible Assets, net	20,275	21,765
Loan Receivable	5,000	5,000
Property Held for Sale	1,949	0
Other Assets	2,300	2,554
Total Assets	435,142	454,249
Liabilities:
Accounts Payable and Accrued Expenses	1,000	1,659
Revolving Credit Facility	1,000	1,000
Loan Payable, net	997	1,986
Dividends and Distributions Payable	8,231	8,512
Security Deposits	7,338	7,774
Rent Received in Advance	907	1,375
Other Liabilities	199	1,005
Total Liabilities	19,672	23,311
Commitments and Contingencies
Equity:
Preferred Stock, $0.01 Par Value, 100,000,000 Shares Authorized, 0 and 0 Shares Issued and Outstanding, Respectively	0	0
Common Stock, $0.01 Par Value, 400,000,000 Shares Authorized, 20,694,363 and 21,408,194 Shares Issued and Outstanding, Respectively	207	214
Additional Paid-In Capital	447,531	455,822
Accumulated Deficit	(39,635)	(32,487)
Total Stockholders' Equity	408,103	423,549
Noncontrolling Interests	7,367	7,389
Total Equity	415,470	430,938
Total Liabilities and Equity	$ 435,142	$ 454,249

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Preferred Stock, Par Value (in dollars per share)	$ 0.01	$ 0.01
Preferred Stock, Shares Authorized (in shares)	100,000,000	100,000,000
Preferred Stock, Shares Issued (in shares)	0	0
Preferred Stock, Shares Outstanding (in shares)	0	0
Common Stock, Par Value (in dollars per share)	$ 0.01	$ 0.01
Common Stock, Shares Authorized (in shares)	400,000,000	400,000,000
Common Stock, Shares Issued (in shares)	20,694,363	21,408,194
Common Stock, Shares Outstanding (in shares)	20,694,363	21,408,194

Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue:
Rental Income	$ 11,297	$ 11,595	$ 33,637	$ 30,217
Interest Income from Loans	131	434	390	2,301
Fees and Reimbursables	63	49	256	239
Total Revenue	11,491	12,078	34,283	32,757
Expenses:
Depreciation and Amortization Expense	3,568	3,630	10,698	9,113
General and Administrative Expenses:
Compensation Expense	1,173	1,040	3,450	5,100
Professional Fees	300	279	986	1,486
Other General and Administrative Expenses	467	419	1,537	1,387
Total General and Administrative Expenses	1,940	1,738	5,973	7,973
Total Expenses	5,508	5,368	16,671	17,086
Loss on Sale of Real Estate	0	0	0	(60)
Income From Operations	5,983	6,710	17,612	15,611
Other Income (Expenses):
Other Income	178	7	607	103
Interest Expense	(95)	(94)	(284)	(167)
Total Other Income (Expense)	83	(87)	323	(64)
Net Income	6,066	6,623	17,935	15,547
Net Income Attributable to Noncontrolling Interests	(108)	(113)	(312)	(262)
Net Income Attributable to Common Stockholders	$ 5,958	$ 6,510	$ 17,623	$ 15,285
Net Income Attributable to Common Stockholders Per Share - Basic (in dollars per share)	$ 0.28	$ 0.30	$ 0.83	$ 0.71
Net Income Attributable to Common Stockholders Per Share - Diluted (in dollars per share)	$ 0.28	$ 0.30	$ 0.83	$ 0.71
Weighted Average Shares of Common Stock Outstanding - Basic (in shares)	21,199,638	21,428,905	21,330,046	21,417,149
Weighted Average Shares of Common Stock Outstanding - Diluted (in shares)	21,582,314	21,802,487	21,710,101	21,815,763

Consolidated Statements of Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Noncontrolling Interest
Beginning balance (in shares) at Dec. 31, 2021		21,235,914
Beginning balance at Dec. 31, 2021	$ 439,335	$ 213	$ 450,916	$ (23,574)	$ 11,780
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of Vested RSUs to Common Stock (in shares)		88,182
Conversion of Vested RSUs to Common Stock	0	$ 1	125		(126)
Conversion of OP Units to Common Stock (in shares)		79,721
Conversion of OP Units to Common Stock	0		1,586		(1,586)
Stock-Based Compensation	1,201		1,201
Dividends to Common Stock	(22,410)			(22,410)
Dividend Equivalents to Restricted Stock Units	(112)			(112)
Distributions to OP Unit Holders	(398)				(398)
Adjustment for Noncontrolling Interest Ownership in Operating Partnership	0		2,524		(2,524)
Net Income	15,547			15,285	262
Ending balance (in shares) at Sep. 30, 2022		21,403,817
Ending balance at Sep. 30, 2022	433,163	$ 214	456,352	(30,811)	7,408
Beginning balance (in shares) at Dec. 31, 2021		21,235,914
Beginning balance at Dec. 31, 2021	439,335	$ 213	450,916	(23,574)	11,780
Ending balance (in shares) at Dec. 31, 2022		21,408,194
Ending balance at Dec. 31, 2022	430,938	$ 214	455,822	(32,487)	7,389
Beginning balance (in shares) at Jun. 30, 2022		21,318,637
Beginning balance at Jun. 30, 2022	434,323	$ 213	456,083	(29,395)	7,422
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of Vested RSUs to Common Stock (in shares)		85,180
Conversion of Vested RSUs to Common Stock	0	$ 1	(1)
Conversion of OP Units to Common Stock (in shares)		0
Stock-Based Compensation	280		280
Dividends to Common Stock	(7,919)			(7,919)
Dividend Equivalents to Restricted Stock Units	(7)			(7)
Distributions to OP Unit Holders	(137)				(137)
Adjustment for Noncontrolling Interest Ownership in Operating Partnership	0		(10)		10
Net Income	6,623			6,510	113
Ending balance (in shares) at Sep. 30, 2022		21,403,817
Ending balance at Sep. 30, 2022	433,163	$ 214	456,352	(30,811)	7,408
Beginning balance (in shares) at Dec. 31, 2022		21,408,194
Beginning balance at Dec. 31, 2022	$ 430,938	$ 214	455,822	(32,487)	7,389
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of OP Units to Common Stock (in shares)		0
Repurchase of Common Stock (in shares)	(713,831)	(713,831)
Repurchase of Common Stock	$ (9,254)	$ (7)	(9,247)
Stock-Based Compensation	1,060		1,060
Dividends to Common Stock	(24,709)			(24,709)
Dividend Equivalents to Restricted Stock Units	(62)			(62)
Distributions to OP Unit Holders	(438)				(438)
Adjustment for Noncontrolling Interest Ownership in Operating Partnership	0		(104)		104
Net Income	17,935			17,623	312
Ending balance (in shares) at Sep. 30, 2023		20,694,363
Ending balance at Sep. 30, 2023	415,470	$ 207	447,531	(39,635)	7,367
Beginning balance (in shares) at Jun. 30, 2023		21,302,515
Beginning balance at Jun. 30, 2023	425,176	$ 213	455,143	(37,508)	7,328
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of OP Units to Common Stock (in shares)		0
Repurchase of Common Stock (in shares)		(608,152)
Repurchase of Common Stock	(7,920)	$ (6)	(7,914)
Stock-Based Compensation	379		379
Dividends to Common Stock	(8,071)			(8,071)
Dividend Equivalents to Restricted Stock Units	(14)			(14)
Distributions to OP Unit Holders	(146)				(146)
Adjustment for Noncontrolling Interest Ownership in Operating Partnership	0		(77)		77
Net Income	6,066			5,958	108
Ending balance (in shares) at Sep. 30, 2023		20,694,363
Ending balance at Sep. 30, 2023	$ 415,470	$ 207	$ 447,531	$ (39,635)	$ 7,367

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Cash Flows from Operating Activities:
Net Income	$ 6,066	$ 6,623	$ 17,935	$ 15,547
Adjustments to Reconcile Net Income to Net Cash Provided by Operating Activities:
Stock-Based Compensation			1,060	1,201
Loss on Sale of Real Estate	0	0	0	60
Depreciation and Amortization Expense			10,698	9,113
Amortization of Debt Issuance Costs			201	72
Amortization of Debt Discount			10	20
Non-Cash Application of Security Deposit			(945)	0
Changes in Assets and Liabilities
Other Assets			22	(1,618)
Accounts Payable and Accrued Expenses			(659)	577
Security Deposits			510	1,263
Interest Reserve			0	(2,144)
Rent Received in Advance			(468)	(567)
Other Liabilities			(761)	0
Net Cash Provided by Operating Activities			27,603	23,524
Cash Flows from Investing Activities:
Funding of Tenant Improvements			(5,609)	(43,518)	$ (45,245)
Investment in Loans Receivable			0	(5,000)
Acquisition of Real Estate			(350)	(35,419)
Disposition of Real Estate			0	761
Net Cash Used in Investing Activities			(5,959)	(83,176)
Cash Flows from Financing Activities:
Repurchase of Common Stock			(9,254)	0
Common Stock Dividends Paid			(24,987)	(21,074)
Restricted Stock Units Dividend Equivalents Paid			(65)	(147)
Distributions to OP Unit Holders			(437)	(401)
Borrowings from Revolving Credit Facility			0	1,000
Principal Repayment on Loan Payable			(1,000)	(1,800)
Deferred Financing Costs			(28)	0
Net Cash Used in Financing Activities			(35,771)	(22,422)
Net (Decrease) in Cash and Cash Equivalents			(14,127)	(82,074)
Cash and Cash Equivalents - Beginning of Period			45,192	127,097	127,097
Cash and Cash Equivalents - End of Period	31,065	45,023	31,065	45,023	45,192
Supplemental Disclosure of Cash Flow Information:
Interest Paid			123	15
Supplemental Disclosure of Non-Cash Investing and Financing Activities:
Dividends and Distributions Declared, Not Paid	$ 8,231	$ 8,064	8,231	8,064	$ 8,512
Conversion of Mortgage Loan Receivable to Real Estate			0	30,000
Operating lease liability for obtaining right of use asset			$ 0	$ 277

Organization	9 Months Ended
Organization	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	OrganizationNewLake Capital Partners, Inc. (the “Company”), a Maryland corporation, was formed on April 9, 2019, originally as GreenAcreage Real Estate Corp. (“GARE”). The Company is an internally managed Real Estate Investment Trust (“REIT”) focused on providing long-term, single-tenant, triple-net sale-leaseback and build-to-suit transactions for the cannabis industry. The Company conducts its business through its subsidiary, NLCP Operating Partnership LP, a Delaware limited partnership (the “Operating Partnership” or “OP”). The Company holds a controlling equity interest in the Operating Partnership and is the sole general partner. The Company's common stock trades on the OTCQX® Best Market operated by the OTC Markets Group, Inc., under the symbol “NLCP”.

Basis of Presentation and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation The consolidated financial statements include the accounts of the Company, the Operating Partnership, as well as wholly owned subsidiaries of the Operating Partnership and variable interest entities ("VIEs") in which the Company is considered the primary beneficiary. The accompanying unaudited financial statements and related notes have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) for interim financial statements and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. All significant intercompany balances and transactions have been eliminated in the consolidated financial statements. In management's opinion, all adjustments (which include only normal recurring adjustments) necessary to present fairly the Company’s financial position, results of operations and cash flows have been made. The results of operations for the three and nine months ended September 30, 2023 are not necessarily indicative of the operating results for the full year or any future period. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, and filed with the Securities and Exchange Commission (“SEC”) on March 9, 2023. Substantially all of the Company's asset are held by and all of its operations are conducted through the Operating Partnership. The Company is the sole managing general partner of the Operating Partnership. Noncontrolling investors in the Operating Partnership are included in Noncontrolling Interest in the Company's consolidated financial statements. Refer to Note 8 for details. The Operating Partnership is a VIE because the holders of limited partnership interests do not have substantive kick-out rights or participating rights. Furthermore, the Company is the primary beneficiary of the Operating Partnership because it has the obligation to absorb losses and the right to receive benefits from the Operating Partnership and the exclusive power to direct the activities of the Operating Partnership. As of September 30, 2023 and December 31, 2022, the assets and liabilities of the Company and the Operating Partnership are substantially the same, as the Company does not have any significant assets other than its investment in the Operating Partnership. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Management will adjust such estimates when facts and circumstances dictate. Such estimates include, but are not limited to, useful lives for depreciation of property, the fair value and impairment of property and in-place lease intangibles acquired, and the fair value of stock-based compensation. Actual results could differ from those estimates. Reclassification Certain prior year balances have been reclassified to conform to the Company's current year presentation. Significant Accounting Policies There have been no changes to the Company's accounting polices included in Note 2 to the Consolidated Financial Statements of the Company's Annual Report on Form 10-K for the year ended December 31, 2022, except as follows: Property Held for Sale The Company classifies real estate held for sale when the following criteria are met: (i) management commits to a plan to sell the property, (ii) the property is available for sale, (iii) the property is actively being marketed for sale at a price that is reasonable, (iv) the sale of the property within one year is considered probable, and (v) significant change to the plan to sell the property is not expected. A real estate asset held for sale is classified as "Property Held for Sale" in the consolidated balance sheets. A property classified as held for sale is no longer depreciated and is required to be reported at the lower of its carrying value or its fair value less cost to sell. Financial Instruments - Credit Losses The Company adopted Accounting Standards Codification ("ASC") ASC 326, Financial Instruments - Credit Losses ("CECL") on January 1, 2023, which did not have a material impact to its financial statements. The CECL expected loss model requires an allowance for all expected credit losses for the life of a loan be recognized when the loan is either originated or acquired. The allowance for credit losses is a valuation account that is deducted from, or added to, the amortized cost basis of the financial asset(s) to present the net amount expected to be collected on the financial asset(s). At each reporting period, the company will update its estimate and adjust the allowance for credit losses accordingly. Increases in the allowance are recorded through net income as credit loss expense. Decreases in the allowance are recorded through net income as a reversal of credit loss expense. This standard does not specify a specific measurement technique for estimating expected credit losses. Approaches can vary based on a variety of factors. The Company generally uses a discounted cash flow model approach to determine the credit loss, if any, for its financial instruments subject to the CECL guidance.

Real Estate

9 Months Ended

Sep. 30, 2023

Real Estate [Abstract]

Real Estate


Tenant		Market	Site Type	Land		Building and Improvements		Total Real Estate		Accumulated Depreciation		Net Real Estate
Acreage		Connecticut	Dispensary	$	395	$	534	$	929	$	(71)	$	858
Acreage		Massachusetts	Cultivation	481		9,310		9,791		(1,091)		8,700
Acreage		Pennsylvania	Cultivation	952		9,209		10,161		(1,042)		9,119
Ayr Wellness, Inc.		Nevada	Cultivation	1,002		12,577		13,579		(484)		13,095
Ayr Wellness, Inc.		Pennsylvania	Cultivation	2,964		11,565		14,529		(512)		14,017
Bloom Medicinal	(1)	Missouri	Cultivation	948		14,346		15,294		(419)		14,875
Calypso Enterprises		Pennsylvania	Cultivation	1,486		28,514		30,000		(1,168)		28,832
Columbia Care		California	Dispensary	1,082		2,692		3,774		(219)		3,555
Columbia Care		Illinois	Dispensary	162		1,053		1,215		(83)		1,132
Columbia Care		Illinois	Cultivation	801		10,560		11,361		(838)		10,523
Columbia Care		Massachusetts	Dispensary	108		2,212		2,320		(194)		2,126
Columbia Care		Massachusetts	Cultivation	1,136		12,690		13,826		(1,348)		12,478
Cresco Labs		Illinois	Cultivation	276		50,456		50,732		(5,368)		45,364
Curaleaf		Connecticut	Dispensary	184		2,748		2,932		(232)		2,700
Curaleaf		Florida	Cultivation	388		75,595		75,983		(5,765)		70,218
Curaleaf		Illinois	Dispensary	69		525		594		(46)		548
Curaleaf		Illinois	Dispensary	65		959		1,024		(87)		937
Curaleaf		Illinois	Dispensary	606		1,128		1,734		(101)		1,633
Curaleaf		Illinois	Dispensary	281		3,072		3,353		(266)		3,087
Curaleaf		North Dakota	Dispensary	779		1,395		2,174		(124)		2,050
Curaleaf		Ohio	Dispensary	574		2,788		3,362		(281)		3,081
Curaleaf		Pennsylvania	Dispensary	877		1,041		1,918		(118)		1,800
Curaleaf		Pennsylvania	Dispensary	216		2,011		2,227		(174)		2,053
Greenlight	(2)	Arkansas	Dispensary	238		1,919		2,157		(166)		1,991
Mint	(3)	Arizona	Cultivation	2,400		12,907		15,307		—		15,307
Organic Remedies		Missouri	Cultivation	204		20,897		21,101		(1,910)		19,191
PharmaCann		Massachusetts	Dispensary	411		1,701		2,112		(261)		1,851
PharmaCann		Ohio	Dispensary	281		1,269		1,550		(33)		1,517
PharmaCann		Pennsylvania	Dispensary	44		1,271		1,315		(100)		1,215
Revolutionary Clinics		Massachusetts	Cultivation	926		41,934		42,860		(2,768)		40,092
Trulieve		Pennsylvania	Cultivation	1,061		43,209		44,270		(3,662)		40,608
Total Real Estate(4)				$	21,397	$	382,087	$	403,484	$	(28,931)	$	374,553

(1) A portion of this investment is currently under development. Once the expansion is completed and placed in service, the Company will begin depreciating this part of the property.

(2) GL Partners, Inc. (Greenlight) took over as tenant, however Curaleaf remains the guarantor subject to certain conditions in the lease agreement.

(3) This property is under development. Once completed and placed in service, the Company will start depreciating this property.

(4) The table does not include one property held for sale.

Note 3 - Real Estate (continued)

Real Estate Acquisitions

The following table presents the real estate acquisition for the nine months ended September 30, 2023 (in thousands):

Tenant

Market

Site Type

Closing Date

Real Estate Acquisition Costs

Bloom Medicinal

Missouri

Cultivation

March 3, 2023

350

(1)

Total

350

(1)The Company exercised its option to purchase the adjacent parcel of land to expand its cultivation facility in Missouri and has committed to fund $16.2 million for the expansion.

Tenant

Market

Site Type

Closing Date

Real Estate Acquisition Costs(1)

Bloom Medicinal

Missouri

Cultivation

April 1, 2022

7,301

(2)

Ayr Wellness, Inc.

Pennsylvania

Cultivation

June 30, 2022

14,529

Ayr Wellness, Inc.

Nevada

Cultivation

June 30, 2022

13,579

Calypso Enterprises

Pennsylvania

Cultivation

August 5, 2022

30,000

(3)

PharmaCann

Ohio

Dispensary

November 3, 2022

1,550

Total

66,959

(2) Includes approximately $5.0 million of TI funded at closing of the property.

(3) The Company entered into a $30.0 million mortgage loan on October 29, 2021, which converted to a sale-leaseback on August 5, 2022.

Conversion of Mortgage Loan

Note 3 - Real Estate (continued)

Tenant Improvements Funded


Tenant	Market	Site Type	Closing Date	TI Funded			Unfunded Commitments
Mint	Arizona	Cultivation	June 24, 2021	$	2,366		$	5,703	(1)
Organic Remedies	Missouri	Cultivation	December 20, 2021	282			—
Bloom Medicinal	Missouri	Cultivation	April 1, 2022	2,961		(2)	13,722
Ayr Wellness, Inc.	Pennsylvania	Cultivation	June 30, 2022	—			750




Total				$	5,609		$	20,175

(1) Effective June 1, 2023, the lease agreement was amended to include an additional TI commitment of approximately $6.5 million.

(2)Approximately $534 thousand of the TI funded related to our commitment prior to exercising our option related to the additional parcel.

Tenant

Market

Site Type

Closing Date

TI Funded

Unfunded Commitments

Curaleaf

Florida

Cultivation

August 4, 2020

20,983

(1)

—

Mint

Massachusetts

Cultivation

April 1, 2021

349

—

Mint

Arizona

Cultivation

June 24, 2021

7,415

1,554

(2)

PharmaCann

Massachusetts

Dispensary

March 17, 2021

—

Trulieve

Pennsylvania

Cultivation

March 17, 2021

7,046

(3)

—

Organic Remedies

Missouri

Cultivation

December 20, 2021

4,745

282

Bloom Medicinal

Missouri

Cultivation

April 1, 2022

4,682

534

(4)

Ayr Wellness, Inc.

Pennsylvania

Cultivation

June 30, 2022

—

750

Total

45,245

3,120

(1) On June 16, 2022, the Company funded the expansion of an existing property.

(2) The tenant had been paying rent for the remaining commitment since July 2022 in accordance with the lease agreement.

(3) The tenant had been paying rent for the TI since December 2021 in accordance with the lease agreement. As of May 2022, the TI had been fully funded.

(4) The unfunded commitment did not include an option, because the Company did not have an obligation to acquire the adjacent property from an existing tenant and fund TIs.

Disposal of Real Estate

There were no sales of real estate during the nine months ended September 30, 2023.

Note 3 - Real Estate (continued)

Real Estate Held for Sale

Construction in Progress

Depreciation and Amortization

In-place Leases

The following table presents the future amortization of the Company’s acquired in-place leases as of September 30, 2023 (in thousands):


Year	Amortization Expense
2023 (three months ending December 31, 2023)	$	496
2024	1,985
2025	1,985
2026	1,985
2027	1,985
Thereafter	11,839
Total	$	20,275

Impairment

Leases

9 Months Ended

Sep. 30, 2023

Leases [Abstract]

Leases

As Lessor

The following table presents the future contractual minimum rent under the Company’s operating leases as of September 30, 2023 (in thousands):


Year	Contractual Minimum Rent(1)
2023 (three months ending December 31, 2023)	$	12,463
2024	52,076
2025	54,333
2026	55,734
2027	57,171
Thereafter	609,709
Total	$	841,486

Concentration of Credit Risk

Note 4 - Leases (continued)

The following table presents the five tenants in the Company's portfolio that represented the largest percentage of the Company's recognized rental income for each of the periods presented:


For the Three Months Ended September 30,
2023				2022
Tenant	Number of Leases		Percentage of Rental Income(1)	Tenant		Number of Leases	Percentage of Rental Income(1)
Curaleaf	10		25%	Curaleaf		10	25%
Cresco Labs	1		15%	Cresco Labs		1	17%
Trulieve	1		12%	Trulieve		1	14%
Columbia Care	5		9%	Revolutionary Clinics	(3)	1	13%
Calypso	1	(2)	8%	Columbia Care		5	10%

(1) Calculated based on rental income received during the period. This amount excludes revenue from fees and reimbursements.


For the Nine Months Ended September 30,
2023				2022
Tenant	Number of Leases		Percentage of Rental Income(1)	Tenant		Number of Leases	Percentage of Rental Income(1)
Curaleaf	10		25%	Curaleaf		10	25%
Cresco Labs	1		14%	Cresco Labs		1	16%
Trulieve	1		12%	Trulieve		1	13%
Columbia Care	5		9%	Revolutionary Clinics	(3)	1	13%
Calypso	1	(2)	8%	Columbia Care		5	10%

(1) Calculated based on rental income received during the period. This amount excludes revenue from fees and reimbursements.

(3) This tenant failed to pay rental income during the nine months ended September 30, 2023. A security deposit of approximately $945 thousand was applied towards the outstanding rent.

Non-Performing Tenant

Note 4 - Leases (continued)

As Lessee

The following table presents the future contractual rent obligations as lessee as of September 30, 2023 (in thousands):


Year	Contractual Base Rent
2023 (three months ended December 31, 2023)	$	19
2024	75
2025	77
2026	52


Total Minimum Lease Payments	$	223
Less: Amount Discounted Using Incremental Borrowing Rate	$	84
Total Lease Liability	$	139

As of September 30, 2023, the weighted-average discount rate used to calculate the lease liability was 5.65% and the remaining lease term was 2.92 years.

Leases

As Lessor

The following table presents the future contractual minimum rent under the Company’s operating leases as of September 30, 2023 (in thousands):


Year	Contractual Minimum Rent(1)
2023 (three months ending December 31, 2023)	$	12,463
2024	52,076
2025	54,333
2026	55,734
2027	57,171
Thereafter	609,709
Total	$	841,486

Concentration of Credit Risk

Note 4 - Leases (continued)

The following table presents the five tenants in the Company's portfolio that represented the largest percentage of the Company's recognized rental income for each of the periods presented:


For the Three Months Ended September 30,
2023				2022
Tenant	Number of Leases		Percentage of Rental Income(1)	Tenant		Number of Leases	Percentage of Rental Income(1)
Curaleaf	10		25%	Curaleaf		10	25%
Cresco Labs	1		15%	Cresco Labs		1	17%
Trulieve	1		12%	Trulieve		1	14%
Columbia Care	5		9%	Revolutionary Clinics	(3)	1	13%
Calypso	1	(2)	8%	Columbia Care		5	10%

(1) Calculated based on rental income received during the period. This amount excludes revenue from fees and reimbursements.


For the Nine Months Ended September 30,
2023				2022
Tenant	Number of Leases		Percentage of Rental Income(1)	Tenant		Number of Leases	Percentage of Rental Income(1)
Curaleaf	10		25%	Curaleaf		10	25%
Cresco Labs	1		14%	Cresco Labs		1	16%
Trulieve	1		12%	Trulieve		1	13%
Columbia Care	5		9%	Revolutionary Clinics	(3)	1	13%
Calypso	1	(2)	8%	Columbia Care		5	10%

(1) Calculated based on rental income received during the period. This amount excludes revenue from fees and reimbursements.

(3) This tenant failed to pay rental income during the nine months ended September 30, 2023. A security deposit of approximately $945 thousand was applied towards the outstanding rent.

Non-Performing Tenant

Note 4 - Leases (continued)

As Lessee

The following table presents the future contractual rent obligations as lessee as of September 30, 2023 (in thousands):


Year	Contractual Base Rent
2023 (three months ended December 31, 2023)	$	19
2024	75
2025	77
2026	52


Total Minimum Lease Payments	$	223
Less: Amount Discounted Using Incremental Borrowing Rate	$	84
Total Lease Liability	$	139

As of September 30, 2023, the weighted-average discount rate used to calculate the lease liability was 5.65% and the remaining lease term was 2.92 years.

Loan Receivable	9 Months Ended
Loan Receivable	Sep. 30, 2023
Loans and Leases Receivable Disclosure [Abstract]
Loan Receivable	Loan Receivable The Company funded a $5.0 million unsecured loan to Bloom Medicinals on June 10, 2022. The loan initially bore interest at a rate of 10.25% and is structured to increase annually in April by the product of 1.0225 times the interest rate in effect immediately prior to the anniversary date. The loan can be prepaid at any time without penalty and matures on June 30, 2026. The loan is cross defaulted with their lease agreement with the Company. As of September 30, 2023, the aggregate principal amount outstanding on the unsecured loan receivable was $5.0 million with an interest rate of 10.48%. CECL Reserve The Company adopted CECL on January 1, 2023, which did not have a material impact on its financial statements. The Company has only one $5.0 million unsecured loan (discussed above) subject to this guidance, since originating loans is not a core asset class. Estimating the CECL reserve requires significant judgement and based on the Company's analysis as of September 30, 2023, the reserve was de-minimis.

Financings	9 Months Ended
Financings	Sep. 30, 2023
Debt Disclosure [Abstract]
Financings	Financings Seller Financing In connection with the purchase and leaseback of a cultivation facility in Chaffee, Missouri on December 20, 2021, the Company entered into a $3.8 million loan payable to the seller, which is an independent third party from the tenant. The loan bears interest at a rate of 4.0% per annum. Principal on the loan is payable in annual installments of which $1.8 million and $1.0 million were paid in January 2022 and January 2023, respectively. The remaining principal of $1.0 million and accrued interest is payable in January 2024. The loan's outstanding balance as of September 30, 2023 was $1.0 million and the remaining unamortized discount was $3.4 thousand. Revolving Credit Facility On May 6, 2022, the Company's Operating Partnership entered into a loan and security agreement (the “Loan and Security Agreement”) with a commercial federally regulated bank, as a lender and as agent for lenders that become party thereto from time to time (the “Agent”). The Loan and Security Agreement matures on May 6, 2027. The Loan and Security Agreement provides, subject to the Accordion Feature described below, $30.0 million in aggregate commitments for secured revolving loans (“Revolving Credit Facility”), the availability of which is based on a borrowing base consisting of fee simple owned real properties that satisfy eligibility criteria specified in the Loan and Security Agreement and the lease income thereunder which are owned by certain subsidiaries of the Operating Partnership. On July 29, 2022, the Operating Partnership, entered into an amendment to the Revolving Credit Facility, amending the Loan and Security Agreement, to increase the aggregate commitment under the Revolving Credit Facility from $30.0 million to $90.0 million and added two additional lenders. The Loan and Security Agreement also allows the Company, subject to certain conditions, to request additional revolving incremental loan commitments such that the Revolving Credit Facility may be increased to a total aggregate principal amount of up to $100.0 million. Borrowings under the Revolving Credit Facility may be voluntarily prepaid and re-borrowed, subject to certain fees. The Revolving Credit Facility bears a fixed rate of 5.65% for the first three years and thereafter a variable rate based upon the greater of (a) the Prime Rate quoted in the Wall Street Journal (Western Edition) (“Base Rate”) plus an applicable margin of 1.0% or (b) 4.75%. As of September 30, 2023, the Company had approximately $1.0 million in borrowings under the Revolving Credit Facility and $89.0 million in funds available to be drawn, subject to sufficient collateral in the borrowing base. The facility is subject to certain liquidity and operating covenants and includes customary representations and warranties, affirmative and negative covenants and events of default. As of September 30, 2023, the Company complied with the terms of such covenants.

Related Party Transactions	9 Months Ended
Related Party Transactions	Sep. 30, 2023
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions Merger Agreement In connection with the merger, pursuant to which we combined the Company with a separate company that owned a portfolio of dispensaries and cultivation facilities utilized in the cannabis industry, and renamed ourselves NewLake Capital Partners, Inc. (the "Merger") on March 17, 2021, the Company entered into an Investor Rights Agreement (the "Investor Rights Agreement"). The Investor Rights Agreement provides the stockholders party thereto with certain rights with respect to the nomination of members to the Company's board of directors. Prior to the completion of the Company's IPO, pursuant to the Investor Rights Agreement, HG Vora Capital Management, LLC (“HG Vora”) had the right to nominate four directors to our board of directors. Following the completion of our IPO, for so long as HG Vora owns (i) at least 9% of our issued and outstanding common stock for 60 consecutive days, HG Vora may nominate two of the members of our board of directors, and (ii) at least 5% of our issued and outstanding common stock for 60 consecutive days, HG Vora may nominate one member of our board of directors. If HG Vora owns less than 5% of our issued and outstanding common stock for 60 consecutive days, then HG Vora may not nominate any members of our board of directors pursuant to the Investor Rights Agreement. Following the completion of our IPO, the West Stockholders may nominate one member of our board of directors for so long as the West Stockholders own in the aggregate at least 5% of the issued and outstanding shares of our common stock. If the West Stockholders own in the aggregate less than 5% of our issued and outstanding common stock for 60 consecutive days, then the West Stockholders may not nominate any members of our board of directors pursuant to the Investor Rights Agreement. Following the completion of our IPO, Pangea may nominate one member of our board of directors for so long as Pangea owns at least 4% of our issued and outstanding common stock for 60 consecutive days. If Pangea owns less than 4% of our issued and outstanding common stock for 60 consecutive days, then Pangea may not nominate any members of our board of directors pursuant to the Investor Rights Agreement.

Noncontrolling Interests

9 Months Ended

Sep. 30, 2023

Noncontrolling Interest [Abstract]

Noncontrolling Interests


	September 30, 2023			December 31, 2022
	OP Units	Noncontrolling Interests %		OP Units	Noncontrolling Interests %
Balance at January 1,	373,582	1.7	%	453,303	2.1	%




OP Units Converted	—	—	%	(79,721)	(0.4)	%
Balance at End of Period	373,582	1.7	%	373,582	1.7	%

Stock Based Compensation

9 Months Ended

Sep. 30, 2023

Share-Based Payment Arrangement [Abstract]

Stock Based Compensation

Stock Based CompensationThe Company's board of directors adopted the 2021 Equity Incentive Plan (the “Plan”), to provide employees of the Company and its subsidiaries, certain consultants and advisors who perform services for the Company or its subsidiaries, and non-employee members of the board of directors of the Company with the opportunity to receive grants of incentive stock options, nonqualified stock options, stock appreciation rights, stock awards, stock units, other stock-based awards, and cash awards to enable the Company to motivate, attract and retain the services of directors, officers and employees considered essential to the long term success of the Company. Under the terms of the Plan, the aggregate number of shares of awards will be no more than 2,275,727 shares. If and to the extent shares of awards granted under the Plan, expire or are canceled, forfeited, exchanged or surrendered without having been exercised, or if any stock awards, stock units or other stock-based awards are forfeited, terminated or otherwise not paid in full, the shares subject to such grants shall again be available for issuance or transfer under the Plan. The Plan has a term of ten years until August 12, 2031. As of September 30, 2023, there were approximately 1,912,535 shares available for issuance under the Plan.

Restricted Stock Units

Unvested Restricted Stock Units

The following table sets forth the Company's unvested RSU activity for the nine months ended September 30,:


	For the Nine Months Ended September 30,
	2023			2022
	Number of Unvested Shares of RSUs	Weighted Average Grant Date Fair Value Per Share		Number of Unvested Shares of RSUs	Weighted Average Grant Date Fair Value Per Share
Balance at January 1,	29,255	$	22.89	45,018	$	27.49
Granted	59,031	$	12.87	19,362	$	20.54
Forfeited	—	$	—	(8,566)	27.49
Vested	(18,318)	$	23.54	(20,173)	$	27.49
Balance at September 30,	69,968	$	15.15	35,641	$	23.71

Vested Restricted Stock Units

The following table sets forth the Company's vested RSU activity for the nine months ended September 30,:


	For the Nine Months ended September 30,
	2023			2022
	Number of Vested Shares of RSUs	Weighted Average Grant Date Fair Value Per Share		Number of Vested Shares of RSUs	Weighted Average Grant Date Fair Value Per Share
Balance at January 1,	18,534	$	23.93	127,176	$	21.08
Vested	18,318	20.14		9,493	27.49
Converted	—	—		(118,135)	21.15
Balance at September 30,	36,852	$	22.05	18,534	$	23.93

Performance Stock Units

Performance Stock Units (“PSUs”) are granted to officers and certain employees of the Company. Total outstanding PSUs as of September 30, 2023 and 2022 were 121,858 and 66,841, respectively.

The following table sets forth the Company's unvested performance stock activity for the nine months ended September 30,:


	For the Nine Months Ended September 30,
	2023			2022
	Number of Unvested Shares of PSUs	Weighted Average Grant Date Fair Value Per Share		Number of Unvested Shares of PSUs	Weighted Average Grant Date Fair Value Per Share
Balance at January 1,	66,841	$	24.04	77,742	$	24.04
Granted	55,017	$	11.23	—	$	—

Forfeited	—	—		(10,901)	$	24.03
Balance at September 30,	121,858	$	18.26	66,841	$	24.04

Stock Options

Warrants

9 Months Ended

Sep. 30, 2023

Warrants and Rights Note Disclosure [Abstract]

Warrants

The following table summarizes warrant activity for the nine months ended September 30,:


	2023			2022
	Number of Warrants(1)	Weighted Average Exercise Price		Number of Warrants(1)	Weighted Average Exercise Price
Exercisable at January 1,	602,392	$	24.00	602,392	$	24.00
Granted	—	—		—	—
Exercised	—	—		—	—
Exercisable at September 30,	602,392	$	24.00	602,392	$	24.00

(1) Warrants were granted on March 17, 2021.

Stockholders' Equity

9 Months Ended

Sep. 30, 2023

Stockholders' Equity Note [Abstract]

Stockholders' Equity

Preferred Stock

As of September 30, 2023 and December 31, 2022, the Company had 100,000,000 shares of preferred stock authorized and 0 shares of preferred stock outstanding.

Common Stock

On August 13, 2021, the Company completed its initial public offering ("IPO") of 3,905,950 shares of common stock, with a par value $0.01 per share.

Stock Repurchase Program

legal requirements and other factors. The stock repurchase program may be suspended or discontinued by us at any time and without prior notice.

Conversion of OP Units

Dividends

Declaration Date

Record Date

Period Covered

Distributions Paid Date

Amount per Share/Unit

March 7, 2023

March 31, 2023

January 1, 2023 to March 31, 2023

April 14, 2023

0.39

June 15, 2023

June 30, 2023

April 1, 2023 to June 30, 2023

July 14, 2023

0.39

September 15, 2023

September 29, 2023

July 1, 2023 to September 30, 2023

October 13, 2023

0.39

Total

1.17

Declaration Date

Record Date

Period Covered

Distributions Paid Date

Amount per Share/Unit

March 15, 2022

March 31, 2022

January 1, 2022 to March 31, 2022

April 14, 2022

0.33

June 15, 2022

June 30, 2022

April 1, 2022 to June 30, 2022

July 15, 2022

0.35

September 15, 2022

September 30, 2022

July 1, 2022 to September 30, 2022

October 14, 2022

0.37

Total

1.05

Earnings Per Share

9 Months Ended

Sep. 30, 2023

Earnings Per Share [Abstract]

Earnings Per Share

The following table presents the computation of basic and diluted earnings per share (in thousands, except share data):


	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2023		2022		2023		2022
Numerator:
Net Income Attributable to Common Stockholders	$	5,958	$	6,510	$	17,623	$	15,285

Add: Net Income Attributable to Noncontrolling Interest	108		113		312		262
Net Income	$	6,066	$	6,623	$	17,935	$	15,547

Denominator:
Weighted Average Shares of Common Stock Outstanding - Basic	21,199,638		21,428,905		21,330,046		21,417,149
Dilutive Effect of OP Units	373,582		373,582		373,582		398,614

Dilutive Effect of Unvested Restricted Stock Units	9,094		—		6,473		—
Weighted Average Shares of Common Stock - Diluted	21,582,314		21,802,487		21,710,101		21,815,763

Earnings Per Share - Basic
Net Income Attributable to Common Stockholders	$	0.28	$	0.30	$	0.83	$	0.71
Earnings Per Share - Diluted
Net Income Attributable to Common Stockholders	$	0.28	$	0.30	$	0.83	$	0.71

Fair Value Measurements

9 Months Ended

Sep. 30, 2023

Fair Value Disclosures [Abstract]

Fair Value Measurements

Level 1 – Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2 – Includes other inputs that are directly or indirectly observable in the marketplace.

Level 3 – Unobservable inputs that are supported by little or no market activities, therefore requiring an entity to develop its own assumptions.

The following table presents the carrying value and estimated fair value of financial instruments at September 30, 2023 and December 31, 2022 (in thousands):


	September 30, 2023				December 31, 2022
	Carrying Value		Estimated Fair Value		Carrying Value		Estimated Fair Value
Note Receivable(1)	$	5,000	$	4,800	$	5,000	$	4,952
Revolving Credit Facility(2)	$	1,000	$	952	$	1,000	$	915
Seller Financing(2)	$	997	$	980	$	1,986	$	1,942

(1) The fair value measurement of the $5.0 million Note Receivable is based on unobservable inputs, and as such, is classified as Level III.

(2) The fair value measurement of the Company's Revolving Credit Facility and Seller Financing is based on observable inputs, and as such, is classified as Level II.

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and ContingenciesAs of September 30, 2023, the Company had aggregate unfunded commitments to invest $20.2 million to develop and improve its existing cultivation facilities in Arizona, Missouri, and Pennsylvania. Refer to Note 3 for further details on the Company's commitments. The Company owns a portfolio of properties that it leases to entities which cultivate, harvest, process and distribute cannabis. Cannabis is an illegal substance under the Controlled Substances Act. Although the operations of the Company’s tenants are legalized in the states and local jurisdictions in which they operate, the Company and its tenants are subject to certain risks and uncertainties associated with conducting operations subject to conflicting federal, state and local laws in an industry with a complex regulatory environment which is continuously evolving. These risks and uncertainties include the risk that the strict enforcement of federal laws regarding cannabis would likely result in the Company’s inability, and the inability of its tenants, to execute their respective business plans.

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Tenant Improvements Subsequent to September 30, 2023, the Company funded approximately $2.9 million of tenant improvements for the expansion of the Company's cultivation facilities located in Arizona and Missouri. Leases Revolutionary Clinics In October 2023, the Company entered into a lease amendment and forbearance agreement (the "Agreements”) for its existing lease agreement with Revolutionary Clinics on its cultivation facility in Massachusetts, where Revolutionary Clinics is the sole tenant. Under the terms of the Agreements, the lease term was extended by five years. The Company received $480 thousand of unpaid rent and applied the remaining $315 thousand of security deposit; these amounts will be recognized as income in the fourth quarter of 2023. Additionally, the Company has received October and November contractual rent payments pursuant to the amended lease. The rental payments may escalate as the tenant’s business achieves certain gross revenue metrics. Under the forbearance agreement, the Company provided forbearance for approximately $2.0 million of back rental income. Lastly, the Company received 9.95% of equity in Revolutionary Clinics in the form of warrants. Calypso Calypso did not make its weekly October rent payments. However, it has resumed its weekly rent payments in November. Disposition of Real Estate In October 2023, the Company closed on the sale of its cultivation facility in Palmer, Massachusetts, for $2.0 million, which was leased to Mint. The Company's investment in the property was $1.9 million. Upon closing, Mint's lease agreement was terminated and they paid a portion of the closing costs, resulting in a break-even sale of the property.

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Pay vs Performance Disclosure
Net Income (Loss)	$ 5,958	$ 6,510	$ 17,623	$ 15,285

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Sep. 30, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The consolidated financial statements include the accounts of the Company, the Operating Partnership, as well as wholly owned subsidiaries of the Operating Partnership and variable interest entities ("VIEs") in which the Company is considered the primary beneficiary. The accompanying unaudited financial statements and related notes have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) for interim financial statements and with the instructions to Form 10-Q and Article 10 of Regulation S-X. They do not include all of the information and footnotes required by GAAP for complete financial statements. All significant intercompany balances and transactions have been eliminated in the consolidated financial statements. In management's opinion, all adjustments (which include only normal recurring adjustments) necessary to present fairly the Company’s financial position, results of operations and cash flows have been made. The results of operations for the three and nine months ended September 30, 2023 are not necessarily indicative of the operating results for the full year or any future period. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, and filed with the Securities and Exchange Commission (“SEC”) on March 9, 2023. Substantially all of the Company's asset are held by and all of its operations are conducted through the Operating Partnership. The Company is the sole managing general partner of the Operating Partnership. Noncontrolling investors in the Operating Partnership are included in Noncontrolling Interest in the Company's consolidated financial statements. Refer to Note 8 for details. The Operating Partnership is a VIE because the holders of limited partnership interests do not have substantive kick-out rights or participating rights. Furthermore, the Company is the primary beneficiary of the Operating Partnership because it has the obligation to absorb losses and the right to receive benefits from the Operating Partnership and the exclusive power to direct the activities of the Operating Partnership. As of September 30, 2023 and December 31, 2022, the assets and liabilities of the Company and the Operating Partnership are substantially the same, as the Company does not have any significant assets other than its investment in the Operating Partnership.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Management will adjust such estimates when facts and circumstances dictate. Such estimates include, but are not limited to, useful lives for depreciation of property, the fair value and impairment of property and in-place lease intangibles acquired, and the fair value of stock-based compensation. Actual results could differ from those estimates.
Reclassification	Reclassification Certain prior year balances have been reclassified to conform to the Company's current year presentation.
Property Held for Sale	Property Held for Sale The Company classifies real estate held for sale when the following criteria are met: (i) management commits to a plan to sell the property, (ii) the property is available for sale, (iii) the property is actively being marketed for sale at a price that is reasonable, (iv) the sale of the property within one year is considered probable, and (v) significant change to the plan to sell the property is not expected. A real estate asset held for sale is classified as "Property Held for Sale" in the consolidated balance sheets. A property classified as held for sale is no longer depreciated and is required to be reported at the lower of its carrying value or its fair value less cost to sell.
Financial Instruments - Credit Losses	Financial Instruments - Credit LossesThe Company adopted Accounting Standards Codification ("ASC") ASC 326, Financial Instruments - Credit Losses ("CECL") on January 1, 2023, which did not have a material impact to its financial statements. The CECL expected loss model requires an allowance for all expected credit losses for the life of a loan be recognized when the loan is either originated or acquired. The allowance for credit losses is a valuation account that is deducted from, or added to, the amortized cost basis of the financial asset(s) to present the net amount expected to be collected on the financial asset(s). At each reporting period, the company will update its estimate and adjust the allowance for credit losses accordingly. Increases in the allowance are recorded through net income as credit loss expense. Decreases in the allowance are recorded through net income as a reversal of credit loss expense. This standard does not specify a specific measurement technique for estimating expected credit losses. Approaches can vary based on a variety of factors. The Company generally uses a discounted cash flow model approach to determine the credit loss, if any, for its financial instruments subject to the CECL guidance.

Real Estate (Tables)

9 Months Ended

Sep. 30, 2023

Real Estate [Abstract]

Properties Acquired and Current Properties

The following table presents the Company's held for investment real estate portfolio as of September 30, 2023 (dollars in thousands):


Tenant		Market	Site Type	Land		Building and Improvements		Total Real Estate		Accumulated Depreciation		Net Real Estate
Acreage		Connecticut	Dispensary	$	395	$	534	$	929	$	(71)	$	858
Acreage		Massachusetts	Cultivation	481		9,310		9,791		(1,091)		8,700
Acreage		Pennsylvania	Cultivation	952		9,209		10,161		(1,042)		9,119
Ayr Wellness, Inc.		Nevada	Cultivation	1,002		12,577		13,579		(484)		13,095
Ayr Wellness, Inc.		Pennsylvania	Cultivation	2,964		11,565		14,529		(512)		14,017
Bloom Medicinal	(1)	Missouri	Cultivation	948		14,346		15,294		(419)		14,875
Calypso Enterprises		Pennsylvania	Cultivation	1,486		28,514		30,000		(1,168)		28,832
Columbia Care		California	Dispensary	1,082		2,692		3,774		(219)		3,555
Columbia Care		Illinois	Dispensary	162		1,053		1,215		(83)		1,132
Columbia Care		Illinois	Cultivation	801		10,560		11,361		(838)		10,523
Columbia Care		Massachusetts	Dispensary	108		2,212		2,320		(194)		2,126
Columbia Care		Massachusetts	Cultivation	1,136		12,690		13,826		(1,348)		12,478
Cresco Labs		Illinois	Cultivation	276		50,456		50,732		(5,368)		45,364
Curaleaf		Connecticut	Dispensary	184		2,748		2,932		(232)		2,700
Curaleaf		Florida	Cultivation	388		75,595		75,983		(5,765)		70,218
Curaleaf		Illinois	Dispensary	69		525		594		(46)		548
Curaleaf		Illinois	Dispensary	65		959		1,024		(87)		937
Curaleaf		Illinois	Dispensary	606		1,128		1,734		(101)		1,633
Curaleaf		Illinois	Dispensary	281		3,072		3,353		(266)		3,087
Curaleaf		North Dakota	Dispensary	779		1,395		2,174		(124)		2,050
Curaleaf		Ohio	Dispensary	574		2,788		3,362		(281)		3,081
Curaleaf		Pennsylvania	Dispensary	877		1,041		1,918		(118)		1,800
Curaleaf		Pennsylvania	Dispensary	216		2,011		2,227		(174)		2,053
Greenlight	(2)	Arkansas	Dispensary	238		1,919		2,157		(166)		1,991
Mint	(3)	Arizona	Cultivation	2,400		12,907		15,307		—		15,307
Organic Remedies		Missouri	Cultivation	204		20,897		21,101		(1,910)		19,191
PharmaCann		Massachusetts	Dispensary	411		1,701		2,112		(261)		1,851
PharmaCann		Ohio	Dispensary	281		1,269		1,550		(33)		1,517
PharmaCann		Pennsylvania	Dispensary	44		1,271		1,315		(100)		1,215
Revolutionary Clinics		Massachusetts	Cultivation	926		41,934		42,860		(2,768)		40,092
Trulieve		Pennsylvania	Cultivation	1,061		43,209		44,270		(3,662)		40,608
Total Real Estate(4)				$	21,397	$	382,087	$	403,484	$	(28,931)	$	374,553

(1) A portion of this investment is currently under development. Once the expansion is completed and placed in service, the Company will begin depreciating this part of the property.

(2) GL Partners, Inc. (Greenlight) took over as tenant, however Curaleaf remains the guarantor subject to certain conditions in the lease agreement.

(3) This property is under development. Once completed and placed in service, the Company will start depreciating this property.

(4) The table does not include one property held for sale.

The following table presents the real estate acquisition for the nine months ended September 30, 2023 (in thousands):

Tenant

Market

Site Type

Closing Date

Real Estate Acquisition Costs

Bloom Medicinal

Missouri

Cultivation

March 3, 2023

350

(1)

Total

350

(1)The Company exercised its option to purchase the adjacent parcel of land to expand its cultivation facility in Missouri and has committed to fund $16.2 million for the expansion.

The following table presents the real estate acquisitions for the year ended December 31, 2022 (in thousands):

Tenant

Market

Site Type

Closing Date

Real Estate Acquisition Costs(1)

Bloom Medicinal

Missouri

Cultivation

April 1, 2022

7,301

(2)

Ayr Wellness, Inc.

Pennsylvania

Cultivation

June 30, 2022

14,529

Ayr Wellness, Inc.

Nevada

Cultivation

June 30, 2022

13,579

Calypso Enterprises

Pennsylvania

Cultivation

August 5, 2022

30,000

(3)

PharmaCann

Ohio

Dispensary

November 3, 2022

1,550

Total

66,959

(2) Includes approximately $5.0 million of TI funded at closing of the property.

(3) The Company entered into a $30.0 million mortgage loan on October 29, 2021, which converted to a sale-leaseback on August 5, 2022.

Tenant Improvements Funded

The following table presents the tenant improvements funded for the nine months ended September 30, 2023 (in thousands):


Tenant	Market	Site Type	Closing Date	TI Funded			Unfunded Commitments
Mint	Arizona	Cultivation	June 24, 2021	$	2,366		$	5,703	(1)
Organic Remedies	Missouri	Cultivation	December 20, 2021	282			—
Bloom Medicinal	Missouri	Cultivation	April 1, 2022	2,961		(2)	13,722
Ayr Wellness, Inc.	Pennsylvania	Cultivation	June 30, 2022	—			750




Total				$	5,609		$	20,175

(1) Effective June 1, 2023, the lease agreement was amended to include an additional TI commitment of approximately $6.5 million.

(2)Approximately $534 thousand of the TI funded related to our commitment prior to exercising our option related to the additional parcel.

The following table presents the tenant improvements funded for the year ended December 31, 2022 (in thousands):

Tenant

Market

Site Type

Closing Date

TI Funded

Unfunded Commitments

Curaleaf

Florida

Cultivation

August 4, 2020

20,983

(1)

—

Mint

Massachusetts

Cultivation

April 1, 2021

349

—

Mint

Arizona

Cultivation

June 24, 2021

7,415

1,554

(2)

PharmaCann

Massachusetts

Dispensary

March 17, 2021

—

Trulieve

Pennsylvania

Cultivation

March 17, 2021

7,046

(3)

—

Organic Remedies

Missouri

Cultivation

December 20, 2021

4,745

282

Bloom Medicinal

Missouri

Cultivation

April 1, 2022

4,682

534

(4)

Ayr Wellness, Inc.

Pennsylvania

Cultivation

June 30, 2022

—

750

Total

45,245

3,120

(1) On June 16, 2022, the Company funded the expansion of an existing property.

(2) The tenant had been paying rent for the remaining commitment since July 2022 in accordance with the lease agreement.

(3) The tenant had been paying rent for the TI since December 2021 in accordance with the lease agreement. As of May 2022, the TI had been fully funded.

(4) The unfunded commitment did not include an option, because the Company did not have an obligation to acquire the adjacent property from an existing tenant and fund TIs.

Future Amortization Expense

The following table presents the future amortization of the Company’s acquired in-place leases as of September 30, 2023 (in thousands):


Year	Amortization Expense
2023 (three months ending December 31, 2023)	$	496
2024	1,985
2025	1,985
2026	1,985
2027	1,985
Thereafter	11,839
Total	$	20,275

Leases (Tables)

9 Months Ended

Sep. 30, 2023

Leases [Abstract]

Future Contractual Minimum Rent

The following table presents the future contractual minimum rent under the Company’s operating leases as of September 30, 2023 (in thousands):


Year	Contractual Minimum Rent(1)
2023 (three months ending December 31, 2023)	$	12,463
2024	52,076
2025	54,333
2026	55,734
2027	57,171
Thereafter	609,709
Total	$	841,486

Tenants in Portfolio that Represents the Largest Percentage of Total Revenue

The following table presents the five tenants in the Company's portfolio that represented the largest percentage of the Company's recognized rental income for each of the periods presented:


For the Three Months Ended September 30,
2023				2022
Tenant	Number of Leases		Percentage of Rental Income(1)	Tenant		Number of Leases	Percentage of Rental Income(1)
Curaleaf	10		25%	Curaleaf		10	25%
Cresco Labs	1		15%	Cresco Labs		1	17%
Trulieve	1		12%	Trulieve		1	14%
Columbia Care	5		9%	Revolutionary Clinics	(3)	1	13%
Calypso	1	(2)	8%	Columbia Care		5	10%

(1) Calculated based on rental income received during the period. This amount excludes revenue from fees and reimbursements.


For the Nine Months Ended September 30,
2023				2022
Tenant	Number of Leases		Percentage of Rental Income(1)	Tenant		Number of Leases	Percentage of Rental Income(1)
Curaleaf	10		25%	Curaleaf		10	25%
Cresco Labs	1		14%	Cresco Labs		1	16%
Trulieve	1		12%	Trulieve		1	13%
Columbia Care	5		9%	Revolutionary Clinics	(3)	1	13%
Calypso	1	(2)	8%	Columbia Care		5	10%

(1) Calculated based on rental income received during the period. This amount excludes revenue from fees and reimbursements.

(3) This tenant failed to pay rental income during the nine months ended September 30, 2023. A security deposit of approximately $945 thousand was applied towards the outstanding rent.

Operating Lease Maturity

The following table presents the future contractual rent obligations as lessee as of September 30, 2023 (in thousands):


Year	Contractual Base Rent
2023 (three months ended December 31, 2023)	$	19
2024	75
2025	77
2026	52


Total Minimum Lease Payments	$	223
Less: Amount Discounted Using Incremental Borrowing Rate	$	84
Total Lease Liability	$	139

Noncontrolling Interests (Tables)

9 Months Ended

Sep. 30, 2023

Noncontrolling Interest [Abstract]

Noncontrolling Interest Activity


	September 30, 2023			December 31, 2022
	OP Units	Noncontrolling Interests %		OP Units	Noncontrolling Interests %
Balance at January 1,	373,582	1.7	%	453,303	2.1	%




OP Units Converted	—	—	%	(79,721)	(0.4)	%
Balance at End of Period	373,582	1.7	%	373,582	1.7	%

Stock Based Compensation (Tables)

9 Months Ended

Sep. 30, 2023

Share-Based Payment Arrangement [Abstract]

Unvested Restricted Stock Activity

The following table sets forth the Company's unvested RSU activity for the nine months ended September 30,:


	For the Nine Months Ended September 30,
	2023			2022
	Number of Unvested Shares of RSUs	Weighted Average Grant Date Fair Value Per Share		Number of Unvested Shares of RSUs	Weighted Average Grant Date Fair Value Per Share
Balance at January 1,	29,255	$	22.89	45,018	$	27.49
Granted	59,031	$	12.87	19,362	$	20.54
Forfeited	—	$	—	(8,566)	27.49
Vested	(18,318)	$	23.54	(20,173)	$	27.49
Balance at September 30,	69,968	$	15.15	35,641	$	23.71

Vested Restricted Stock Activity

The following table sets forth the Company's vested RSU activity for the nine months ended September 30,:


	For the Nine Months ended September 30,
	2023			2022
	Number of Vested Shares of RSUs	Weighted Average Grant Date Fair Value Per Share		Number of Vested Shares of RSUs	Weighted Average Grant Date Fair Value Per Share
Balance at January 1,	18,534	$	23.93	127,176	$	21.08
Vested	18,318	20.14		9,493	27.49
Converted	—	—		(118,135)	21.15
Balance at September 30,	36,852	$	22.05	18,534	$	23.93

Unvested Performance Stock Activity

The following table sets forth the Company's unvested performance stock activity for the nine months ended September 30,:


	For the Nine Months Ended September 30,
	2023			2022
	Number of Unvested Shares of PSUs	Weighted Average Grant Date Fair Value Per Share		Number of Unvested Shares of PSUs	Weighted Average Grant Date Fair Value Per Share
Balance at January 1,	66,841	$	24.04	77,742	$	24.04
Granted	55,017	$	11.23	—	$	—

Forfeited	—	—		(10,901)	$	24.03
Balance at September 30,	121,858	$	18.26	66,841	$	24.04

Warrants (Tables)

9 Months Ended

Sep. 30, 2023

Warrants and Rights Note Disclosure [Abstract]

Warrant Activity

The following table summarizes warrant activity for the nine months ended September 30,:


	2023			2022
	Number of Warrants(1)	Weighted Average Exercise Price		Number of Warrants(1)	Weighted Average Exercise Price
Exercisable at January 1,	602,392	$	24.00	602,392	$	24.00
Granted	—	—		—	—
Exercised	—	—		—	—
Exercisable at September 30,	602,392	$	24.00	602,392	$	24.00

(1) Warrants were granted on March 17, 2021.

Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2023

Stockholders' Equity Note [Abstract]

Common Dividends, Dividend Equivalents and Distributions Declared

Declaration Date

Record Date

Period Covered

Distributions Paid Date

Amount per Share/Unit

March 7, 2023

March 31, 2023

January 1, 2023 to March 31, 2023

April 14, 2023

0.39

June 15, 2023

June 30, 2023

April 1, 2023 to June 30, 2023

July 14, 2023

0.39

September 15, 2023

September 29, 2023

July 1, 2023 to September 30, 2023

October 13, 2023

0.39

Total

1.17

Declaration Date

Record Date

Period Covered

Distributions Paid Date

Amount per Share/Unit

March 15, 2022

March 31, 2022

January 1, 2022 to March 31, 2022

April 14, 2022

0.33

June 15, 2022

June 30, 2022

April 1, 2022 to June 30, 2022

July 15, 2022

0.35

September 15, 2022

September 30, 2022

July 1, 2022 to September 30, 2022

October 14, 2022

0.37

Total

1.05

Earnings Per Share (Tables)

9 Months Ended

Sep. 30, 2023

Earnings Per Share [Abstract]

Earnings Per Share

The following table presents the computation of basic and diluted earnings per share (in thousands, except share data):


	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2023		2022		2023		2022
Numerator:
Net Income Attributable to Common Stockholders	$	5,958	$	6,510	$	17,623	$	15,285

Add: Net Income Attributable to Noncontrolling Interest	108		113		312		262
Net Income	$	6,066	$	6,623	$	17,935	$	15,547

Denominator:
Weighted Average Shares of Common Stock Outstanding - Basic	21,199,638		21,428,905		21,330,046		21,417,149
Dilutive Effect of OP Units	373,582		373,582		373,582		398,614

Dilutive Effect of Unvested Restricted Stock Units	9,094		—		6,473		—
Weighted Average Shares of Common Stock - Diluted	21,582,314		21,802,487		21,710,101		21,815,763

Earnings Per Share - Basic
Net Income Attributable to Common Stockholders	$	0.28	$	0.30	$	0.83	$	0.71
Earnings Per Share - Diluted
Net Income Attributable to Common Stockholders	$	0.28	$	0.30	$	0.83	$	0.71

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2023

Fair Value Disclosures [Abstract]

Carrying Value and Estimated Fair Value of Financial Instruments

The following table presents the carrying value and estimated fair value of financial instruments at September 30, 2023 and December 31, 2022 (in thousands):


	September 30, 2023				December 31, 2022
	Carrying Value		Estimated Fair Value		Carrying Value		Estimated Fair Value
Note Receivable(1)	$	5,000	$	4,800	$	5,000	$	4,952
Revolving Credit Facility(2)	$	1,000	$	952	$	1,000	$	915
Seller Financing(2)	$	997	$	980	$	1,986	$	1,942

(1) The fair value measurement of the $5.0 million Note Receivable is based on unobservable inputs, and as such, is classified as Level III.

(2) The fair value measurement of the Company's Revolving Credit Facility and Seller Financing is based on observable inputs, and as such, is classified as Level II.

Real Estate - Narrative (Details) $ in Thousands			1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
Real Estate - Narrative (Details) $ in Thousands	Aug. 05, 2022	Mar. 21, 2022 USD ($) property	Mar. 31, 2023 USD ($) land_parcel	Sep. 30, 2023 USD ($) state property	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($) state property	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($) cultivation_site dispensary	Aug. 25, 2023 USD ($)	Mar. 03, 2023 USD ($)	Oct. 29, 2021 USD ($)
Real Estate [Line Items]
Number of properties \| property				32		32
Number of properties classified as held-for-sale \| property				1		1
Number of states where real estate property is owned \| state				12		12
Real estate acquisition costs						$ 350	$ 35,419
Unfunded commitments				$ 20,175		20,175		$ 3,120
Number of cultivation facilities acquired \| cultivation_site								4
Number of acquired dispensaries \| dispensary								1
Loans receivable				5,000		5,000		$ 5,000
Payments for tenant improvements						5,609	43,518	45,245
Proceeds from sale						0
Real estate held for sale				1,949		1,949		0
Depreciation expense				3,100	$ 3,100	9,200	7,600
Amortization of in-place lease intangible assets				500	$ 500	1,500	1,500
Impairment loss						0	$ 0
Wholly Owned Properties
Real Estate [Line Items]
Real estate acquisition costs			$ 350			$ 350		66,959
HDAI \| Mortgage Receivable
Real Estate [Line Items]
Loans receivable											$ 30,000
Sale lease back term (in years)	20 years
Cultivation Facility In Missouri
Real Estate [Line Items]
Number of parcel of land acquired \| land_parcel			1,000
Unfunded commitments										$ 16,200
Leases, Acquired-in-Place
Real Estate [Line Items]
Acquired in-place lease intangible asset weighted average remaining amortization period (in years)						10 years 6 months
Building and Improvements
Real Estate [Line Items]
Construction in progress				15,300		$ 15,300		$ 12,100
PharmaCann Massachusetts Property
Real Estate [Line Items]
Number of properties \| property		2
Number of properties sold \| property		1
Proceeds from sale		$ 800
Loss on sale		$ 60
Mint Massachusetts Property
Real Estate [Line Items]
Real estate held for sale				1,900		1,900
Escrow deposited into account									$ 100
Nonrefundable escrow deposit				$ 75		$ 75

Real Estate - Properties Acquired and Current Properties (Details) $ in Thousands		1 Months Ended	9 Months Ended		12 Months Ended
	Apr. 01, 2022 USD ($)	Mar. 31, 2023 USD ($)	Sep. 30, 2023 USD ($) property	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)	Mar. 03, 2023 USD ($)	Oct. 29, 2021 USD ($)
Real Estate [Line Items]
Land			$ 21,397		$ 21,427
Building and Improvements			382,087		378,047
Total Real Estate			403,484		399,474
Accumulated Depreciation			(28,931)		(19,736)
Net Real Estate			$ 374,553		379,738
Number of properties classified as held-for-sale \| property			1
Real Estate Acquisition Costs			$ 350	$ 35,419
Payments for tenant improvements			5,609	$ 43,518	45,245
Loans receivable			5,000		5,000
Cultivation Facility In Missouri
Real Estate [Line Items]
Commitment to fund expansion						$ 16,200
Wholly Owned Properties
Real Estate [Line Items]
Real Estate Acquisition Costs		$ 350	350		66,959
Acreage \| Connecticut \| Wholly Owned Properties \| Dispensary
Real Estate [Line Items]
Land			395
Building and Improvements			534
Total Real Estate			929
Accumulated Depreciation			(71)
Net Real Estate			858
Acreage \| Massachusetts \| Wholly Owned Properties \| Cultivation
Real Estate [Line Items]
Land			481
Building and Improvements			9,310
Total Real Estate			9,791
Accumulated Depreciation			(1,091)
Net Real Estate			8,700
Acreage \| Pennsylvania \| Wholly Owned Properties \| Cultivation
Real Estate [Line Items]
Land			952
Building and Improvements			9,209
Total Real Estate			10,161
Accumulated Depreciation			(1,042)
Net Real Estate			9,119
Ayr Wellness, Inc. \| Nevada \| Wholly Owned Properties
Real Estate [Line Items]
Real Estate Acquisition Costs					13,579
Ayr Wellness, Inc. \| Nevada \| Wholly Owned Properties \| Cultivation
Real Estate [Line Items]
Land			1,002
Building and Improvements			12,577
Total Real Estate			13,579
Accumulated Depreciation			(484)
Net Real Estate			13,095
Ayr Wellness, Inc. \| Pennsylvania \| Wholly Owned Properties
Real Estate [Line Items]
Real Estate Acquisition Costs					14,529
Ayr Wellness, Inc. \| Pennsylvania \| Wholly Owned Properties \| Cultivation
Real Estate [Line Items]
Land			2,964
Building and Improvements			11,565
Total Real Estate			14,529
Accumulated Depreciation			(512)
Net Real Estate			14,017
Bloom Medicinal \| Missouri \| Wholly Owned Properties
Real Estate [Line Items]
Real Estate Acquisition Costs			350		7,301
Payments for tenant improvements	$ 5,000
Bloom Medicinal \| Missouri \| Wholly Owned Properties \| Cultivation
Real Estate [Line Items]
Land			948
Building and Improvements			14,346
Total Real Estate			15,294
Accumulated Depreciation			(419)
Net Real Estate			14,875
Calypso Enterprises \| Pennsylvania \| Wholly Owned Properties
Real Estate [Line Items]
Real Estate Acquisition Costs					30,000
Calypso Enterprises \| Pennsylvania \| Wholly Owned Properties \| Mortgage Receivable
Real Estate [Line Items]
Loans receivable							$ 30,000
Calypso Enterprises \| Pennsylvania \| Wholly Owned Properties \| Cultivation
Real Estate [Line Items]
Land			1,486
Building and Improvements			28,514
Total Real Estate			30,000
Accumulated Depreciation			(1,168)
Net Real Estate			28,832
Columbia Care \| California \| Wholly Owned Properties \| Dispensary
Real Estate [Line Items]
Land			1,082
Building and Improvements			2,692
Total Real Estate			3,774
Accumulated Depreciation			(219)
Net Real Estate			3,555
Columbia Care \| Illinois \| Wholly Owned Properties \| Dispensary
Real Estate [Line Items]
Land			162
Building and Improvements			1,053
Total Real Estate			1,215
Accumulated Depreciation			(83)
Net Real Estate			1,132
Columbia Care \| Illinois \| Wholly Owned Properties \| Cultivation
Real Estate [Line Items]
Land			801
Building and Improvements			10,560
Total Real Estate			11,361
Accumulated Depreciation			(838)
Net Real Estate			10,523
Columbia Care \| Massachusetts \| Wholly Owned Properties \| Dispensary
Real Estate [Line Items]
Land			108
Building and Improvements			2,212
Total Real Estate			2,320
Accumulated Depreciation			(194)
Net Real Estate			2,126
Columbia Care \| Massachusetts \| Wholly Owned Properties \| Cultivation
Real Estate [Line Items]
Land			1,136
Building and Improvements			12,690
Total Real Estate			13,826
Accumulated Depreciation			(1,348)
Net Real Estate			12,478
Cresco Labs \| Illinois \| Wholly Owned Properties \| Cultivation
Real Estate [Line Items]
Land			276
Building and Improvements			50,456
Total Real Estate			50,732
Accumulated Depreciation			(5,368)
Net Real Estate			45,364
Curaleaf \| Connecticut \| Wholly Owned Properties \| Dispensary
Real Estate [Line Items]
Land			184
Building and Improvements			2,748
Total Real Estate			2,932
Accumulated Depreciation			(232)
Net Real Estate			2,700
Curaleaf \| Florida \| Wholly Owned Properties \| Cultivation
Real Estate [Line Items]
Land			388
Building and Improvements			75,595
Total Real Estate			75,983
Accumulated Depreciation			(5,765)
Net Real Estate			70,218
Curaleaf \| Illinois \| Wholly Owned Properties \| Dispensary
Real Estate [Line Items]
Land			69
Building and Improvements			525
Total Real Estate			594
Accumulated Depreciation			(46)
Net Real Estate			548
Curaleaf \| Illinois \| Wholly Owned Properties \| Dispensary
Real Estate [Line Items]
Land			65
Building and Improvements			959
Total Real Estate			1,024
Accumulated Depreciation			(87)
Net Real Estate			937
Curaleaf \| Illinois \| Wholly Owned Properties \| Dispensary
Real Estate [Line Items]
Land			606
Building and Improvements			1,128
Total Real Estate			1,734
Accumulated Depreciation			(101)
Net Real Estate			1,633
Curaleaf \| Illinois \| Wholly Owned Properties \| Dispensary
Real Estate [Line Items]
Land			281
Building and Improvements			3,072
Total Real Estate			3,353
Accumulated Depreciation			(266)
Net Real Estate			3,087
Curaleaf \| North Dakota \| Wholly Owned Properties \| Dispensary
Real Estate [Line Items]
Land			779
Building and Improvements			1,395
Total Real Estate			2,174
Accumulated Depreciation			(124)
Net Real Estate			2,050
Curaleaf \| Ohio \| Wholly Owned Properties \| Dispensary
Real Estate [Line Items]
Land			574
Building and Improvements			2,788
Total Real Estate			3,362
Accumulated Depreciation			(281)
Net Real Estate			3,081
Curaleaf \| Pennsylvania \| Wholly Owned Properties \| Dispensary
Real Estate [Line Items]
Land			877
Building and Improvements			1,041
Total Real Estate			1,918
Accumulated Depreciation			(118)
Net Real Estate			1,800
Curaleaf \| Pennsylvania \| Wholly Owned Properties \| Dispensary
Real Estate [Line Items]
Land			216
Building and Improvements			2,011
Total Real Estate			2,227
Accumulated Depreciation			(174)
Net Real Estate			2,053
Greenlight \| Arkansas \| Wholly Owned Properties \| Dispensary
Real Estate [Line Items]
Land			238
Building and Improvements			1,919
Total Real Estate			2,157
Accumulated Depreciation			(166)
Net Real Estate			1,991
Mint \| Arizona \| Wholly Owned Properties \| Cultivation
Real Estate [Line Items]
Land			2,400
Building and Improvements			12,907
Total Real Estate			15,307
Accumulated Depreciation			0
Net Real Estate			15,307
Organic Remedies \| Missouri \| Wholly Owned Properties \| Cultivation
Real Estate [Line Items]
Land			204
Building and Improvements			20,897
Total Real Estate			21,101
Accumulated Depreciation			(1,910)
Net Real Estate			19,191
PharmaCann \| Massachusetts \| Wholly Owned Properties \| Dispensary
Real Estate [Line Items]
Land			411
Building and Improvements			1,701
Total Real Estate			2,112
Accumulated Depreciation			(261)
Net Real Estate			1,851
PharmaCann \| Ohio \| Wholly Owned Properties
Real Estate [Line Items]
Real Estate Acquisition Costs					$ 1,550
PharmaCann \| Ohio \| Wholly Owned Properties \| Dispensary
Real Estate [Line Items]
Land			281
Building and Improvements			1,269
Total Real Estate			1,550
Accumulated Depreciation			(33)
Net Real Estate			1,517
PharmaCann \| Pennsylvania \| Wholly Owned Properties \| Dispensary
Real Estate [Line Items]
Land			44
Building and Improvements			1,271
Total Real Estate			1,315
Accumulated Depreciation			(100)
Net Real Estate			1,215
Revolutionary Clinics \| Massachusetts \| Wholly Owned Properties \| Cultivation
Real Estate [Line Items]
Land			926
Building and Improvements			41,934
Total Real Estate			42,860
Accumulated Depreciation			(2,768)
Net Real Estate			40,092
Trulieve \| Pennsylvania \| Wholly Owned Properties \| Cultivation
Real Estate [Line Items]
Land			1,061
Building and Improvements			43,209
Total Real Estate			44,270
Accumulated Depreciation			(3,662)
Net Real Estate			$ 40,608

Real Estate - Tenant Improvements Funded (Details) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Jun. 01, 2023
Real Estate [Line Items]
Payments for tenant improvements	$ 5,609	$ 43,518	$ 45,245
Unfunded Commitments	20,175		3,120
Arizona \| Mint
Real Estate [Line Items]
Payments for tenant improvements	2,366		7,415
Unfunded Commitments	5,703		1,554	$ 6,500
Missouri \| Organic Remedies
Real Estate [Line Items]
Payments for tenant improvements	282		4,745
Unfunded Commitments	0		282
Missouri \| Bloom Medicinal
Real Estate [Line Items]
Payments for tenant improvements	2,961		4,682
Unfunded Commitments	13,722		534
TI funded related to commitment prior to executing option to additional parcel	534
Pennsylvania \| Ayr Wellness, Inc.
Real Estate [Line Items]
Payments for tenant improvements	0		0
Unfunded Commitments	$ 750		750
Pennsylvania \| Trulieve
Real Estate [Line Items]
Payments for tenant improvements			7,046
Unfunded Commitments			0
Florida \| Curaleaf
Real Estate [Line Items]
Payments for tenant improvements			20,983
Unfunded Commitments			0
Massachusetts \| Mint
Real Estate [Line Items]
Payments for tenant improvements			349
Unfunded Commitments			0
Massachusetts \| PharmaCann
Real Estate [Line Items]
Payments for tenant improvements			25
Unfunded Commitments			$ 0

Real Estate - Future Amortization Expense (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Real Estate [Abstract]
2023 (three months ending December 31, 2023)	$ 496
2024	1,985
2025	1,985
2026	1,985
2027	1,985
Thereafter	11,839
Total	$ 20,275	$ 21,765

Leases - Narrative (Details)	3 Months Ended		9 Months Ended
Leases - Narrative (Details)	Sep. 30, 2023 USD ($) lease	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($) lease	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)	Jun. 30, 2022 USD ($)	Dec. 31, 2020 lease
Lessor, Lease, Description [Line Items]
Reimbursable revenue	$ 14,500	$ 4,900	$ 111,900	$ 138,600
Reimbursable expense	$ 77,900	$ 14,800	$ 228,100	$ 148,400
Number of leases with purchase option \| lease	2		2				2
Total real estate	$ 403,484,000		$ 403,484,000		$ 399,474,000
Number of leases \| lease	1		1
Security deposit remaining for future application	$ 7,338,000		$ 7,338,000		$ 7,774,000
ROU asset						$ 273,000
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]						Other Assets
Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]						Other Liabilities
Weighted-average discount rate	5.65%		5.65%
Remaining lease term (in years)	2 years 11 months 1 day		2 years 11 months 1 day
Revolutionary Clinics
Lessor, Lease, Description [Line Items]
Number of leases \| lease	1		1
Term of contractual rent for security deposit (in months)			3 months
Security deposit applied for tenant default	$ 315,000		$ 945,000
Security deposit remaining for future application	315,000		315,000
Real Estate Investment, Leased Assets with Option to Purchase
Lessor, Lease, Description [Line Items]
Total real estate	$ 6,300,000		$ 6,300,000
Minimum
Lessor, Lease, Description [Line Items]
Percentage of rent increase			2.00%
Term of tenant improvement funding (in months)			12 months
Maximum
Lessor, Lease, Description [Line Items]
Percentage of rent increase			3.00%
Term of tenant improvement funding (in months)			18 months

Leases - Future Contractual Minimum Rent (Details) $ in Thousands	Sep. 30, 2023 USD ($) tenant
Leases [Abstract]
2023 (three months ending December 31, 2023)	$ 12,463
2024	52,076
2025	54,333
2026	55,734
2027	57,171
Thereafter	609,709
Total	$ 841,486
Number of non-performing tenants for future contractual rent \| tenant	1

Leases - Tenants in Portfolio that Represents the Largest Percentage of Total Revenue (Details) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Aug. 31, 2022	Sep. 30, 2023 USD ($) lease	Sep. 30, 2022 lease	Sep. 30, 2023 USD ($) lease	Sep. 30, 2022 lease
Curaleaf
Real Estate [Line Items]
Number Of leases		10	10	10	10
Percentage of Rental Income		25.00%	25.00%	25.00%	25.00%
Cresco Labs
Real Estate [Line Items]
Number Of leases		1	1	1	1
Percentage of Rental Income		15.00%	17.00%	14.00%	16.00%
Trulieve
Real Estate [Line Items]
Number Of leases		1	1	1	1
Percentage of Rental Income		12.00%	14.00%	12.00%	13.00%
Columbia Care
Real Estate [Line Items]
Number Of leases		5	5	5	5
Percentage of Rental Income		9.00%	10.00%	9.00%	10.00%
Revolutionary Clinics
Real Estate [Line Items]
Number Of leases			1		1
Percentage of Rental Income			13.00%		13.00%
Security deposit applied for tenant default \| $		$ 315		$ 945
Calypso
Real Estate [Line Items]
Number Of leases		1		1
Percentage of Rental Income		8.00%		8.00%
Calypso \| Mortgage Receivable
Real Estate [Line Items]
Sale lease back term (in years)	20 years

Leases - Operating Lease Maturity (Details) $ in Thousands	Sep. 30, 2023 USD ($)
Leases [Abstract]
2023 (three months ended December 31, 2023)	$ 19
2024	75
2025	77
2026	52
Total Minimum Lease Payments	223
Less: Amount Discounted Using Incremental Borrowing Rate	84
Total Lease Liability	$ 139

Loan Receivable (Details) $ in Thousands		9 Months Ended
Loan Receivable (Details) $ in Thousands	Jun. 10, 2022 USD ($) Rate	Sep. 30, 2023 USD ($) loan Rate	Dec. 31, 2022 USD ($)
Loans and Leases Receivable Disclosure [Line Items]
Loans receivable \| $		$ 5,000	$ 5,000
Unsecured Loan Receivable \| Bloom Medicinal
Loans and Leases Receivable Disclosure [Line Items]
Loans receivable \| $	$ 5,000	$ 5,000
Loan interest rate \| Rate	10.25%	10.48%
Loan interest rate increase \| Rate	102.25%
Number of unsecured loans held \| loan		1

Financings (Details)	Jul. 29, 2022 USD ($) lender	Jan. 31, 2024 USD ($)	Sep. 30, 2023 USD ($)	Jan. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	May 06, 2022 USD ($)	Jan. 31, 2022 USD ($)	Dec. 20, 2021 USD ($)
Debt Instrument [Line Items]
Revolving Credit Facility			$ 1,000,000		$ 1,000,000
Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 90,000,000.0					$ 30,000,000.0
Number of additional lenders \| lender	2
Minimum variable rate	4.75%
Revolving Credit Facility			1,000,000
Amount available to be drawn			89,000,000
Revolving Credit Facility \| Base Rate
Debt Instrument [Line Items]
Applicable margin	1.00%
Revolving Credit Facility \| Fixed Interest Rate For First Three Years
Debt Instrument [Line Items]
Interest rate	5.65%
Potential Expansion of Borrowing Capacity for Additional Lenders \| Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 100,000,000
Loans Payable
Debt Instrument [Line Items]
Face amount								$ 3,800,000
Interest rate								4.00%
Annual principal payment				$ 1,000,000			$ 1,800,000
Total long-term debt			1,000,000.0
Unamortized discount			$ 3,400
Loans Payable \| Forecast
Debt Instrument [Line Items]
Total long-term debt		$ 1,000,000

Related Party Transactions (Details) - Related Party	9 Months Ended
Related Party Transactions (Details) - Related Party	Sep. 30, 2023 director
HG Vora
Related Party Transaction [Line Items]
Number of directors	4
Number of consecutive days (in days)	60 days
HG Vora \| Related Party, Terms Of Nomination Of Members Of Board Of Directors, Term One
Related Party Transaction [Line Items]
Number of directors	2
Number of consecutive days (in days)	60 days
HG Vora \| Related Party, Terms Of Nomination Of Members Of Board Of Directors, Term Two
Related Party Transaction [Line Items]
Number of directors	1
Number of consecutive days (in days)	60 days
HG Vora \| Common Stock
Related Party Transaction [Line Items]
Minimum ownership percentage	5.00%
HG Vora \| Common Stock \| Related Party, Terms Of Nomination Of Members Of Board Of Directors, Term One
Related Party Transaction [Line Items]
Minimum ownership percentage	9.00%
HG Vora \| Common Stock \| Related Party, Terms Of Nomination Of Members Of Board Of Directors, Term Two
Related Party Transaction [Line Items]
Minimum ownership percentage	5.00%
West Stockholders
Related Party Transaction [Line Items]
Number of directors	1
Number of consecutive days (in days)	60 days
West Stockholders \| Common Stock
Related Party Transaction [Line Items]
Minimum ownership percentage	5.00%
Pangea
Related Party Transaction [Line Items]
Number of directors	1
Number of consecutive days (in days)	60 days
Pangea \| Common Stock
Related Party Transaction [Line Items]
Minimum ownership percentage	4.00%

Noncontrolling Interests (Details) - shares	9 Months Ended				12 Months Ended
Noncontrolling Interests (Details) - shares	Sep. 30, 2023	Sep. 30, 2023	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2022
Noncontrolling Interest [Line Items]
Noncontrolling interest	1.70%	1.70%	1.70%		1.70%	1.70%
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Beginning balance		1.70%	1.70%	2.10%		2.10%
OP Units Converted			0.00%			(0.40%)
Ending balance		1.70%	1.70%			1.70%
Operating Partnership (OP) \| OP Units
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Beginning balance (in shares)	373,582			453,303	453,303
OP Units Converted (in shares)	0				(79,721)
Ending balance (in shares)	373,582				373,582

Stock Based Compensation - Narrative (Details) - USD ($)		3 Months Ended		9 Months Ended		29 Months Ended	36 Months Ended
	Aug. 12, 2021	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2025	Dec. 31, 2024
The 2021 Equity Incentive Plan
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares authorized (in shares)		2,275,727		2,275,727
Term of plan (in years)				10 years
Shares available for issuance (in shares)		1,912,535		1,912,535
Number of shares of common stock upon vesting for each RSU (in shares)				1
Number of shares of common stock upon vesting for dividend paid (in shares)				1
Restricted Stock Units (RSUs)
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares outstanding (in shares)		106,820	54,175	106,820	54,175
Unearned dividend equivalents		$ 88,756	$ 35,850	$ 88,756	$ 35,850
Amortization of compensation costs		200,000	100,000	500,000	800,000
Accelerated expense				0	$ 200,000
Unrecognized compensation cost		700,000		$ 700,000
Weighted average amortization period (in years)				1 year 2 months 12 days
Shares vested in period (in shares)				18,318	20,173
Performance Stock Units (PSU)
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unearned dividend equivalents		$ 0	$ 0	$ 0	$ 0
Performance Stock Units (PSU) \| The 2021 Equity Incentive Plan
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares outstanding (in shares)		121,858	66,841	121,858	66,841
Unearned dividend equivalents		$ 259,546	$ 90,904	$ 259,546	$ 90,904
Amortization of compensation costs		200,000	$ 200,000	600,000	$ 400,000
Unrecognized compensation cost		$ 1,000,000		$ 1,000,000
Weighted average amortization period (in years)				1 year 8 months 12 days
Performance Stock Units (PSU) \| The 2021 Equity Incentive Plan \| Forecast
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares vested in period (in shares)						18,858	55,017	47,983
Fair value (in dollars per share)						$ 24.15	$ 11.23	$ 24.00
Performance Stock Units (PSU) \| The 2021 Equity Incentive Plan \| Minimum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares issued (in shares)		0		0
Performance Stock Units (PSU) \| The 2021 Equity Incentive Plan \| Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares issued (in shares)		243,716		243,716
Nonqualified Stock Options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares issued (in shares)	791,790
Exercise price (in dollars per share)	$ 24.00

Stock Based Compensation - Unvested Restricted Stock Activity (Details) - Restricted Stock Units (RSUs) - $ / shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Number of Unvested Shares of RSUs
Number of Unvested Shares, beginning balance (in shares)	29,255	45,018
Granted (in shares)	59,031	19,362
Forfeited (in shares)	0	(8,566)
Vested (in shares)	(18,318)	(20,173)
Number of Unvested Shares, ending balance (in shares)	69,968	35,641
Weighted Average Grant Date Fair Value Per Share
Weighted Average Grant Date Fair Value Per Share, beginning balance (in dollars per share)	$ 22.89	$ 27.49
Granted (in dollars per share)	12.87	20.54
Forfeited (in dollars per share)	0	27.49
Vested (in dollars per share)	23.54	27.49
Weighted Average Grant Date Fair Value Per Share, ending balance (in dollars per share)	$ 15.15	$ 23.71

Stock Based Compensation - Vested Restricted Stock Activity (Details) - Restricted Stock Units (RSUs) - $ / shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Number of Vested Shares of RSUs
Number of Vested Shares, beginning balance (in shares)	18,534	127,176
Vested (in shares)	18,318	9,493
Converted (in shares)	0	(118,135)
Number of Vested Shares, ending balance (in shares)	36,852	18,534
Weighted Average Grant Date Fair Value Per Share
Weighted Average Grant Date Fair Value Per Share, beginning balance (in dollars per share)	$ 23.93	$ 21.08
Vested (in dollars per share)	20.14	27.49
Converted (in dollars per share)	0	21.15
Weighted Average Grant Date Fair Value Per Share, ending balance (in dollars per share)	$ 22.05	$ 23.93

Stock Based Compensation - Unvested Performance Stock Activity (Details) - Performance Stock Units (PSU) - $ / shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Number of Unvested Shares of PSUs
Number of Unvested Shares, beginning balance (in shares)	66,841	77,742
Grants in period (in shares)	55,017	0
Forfeited (in shares)	0	(10,901)
Number of Unvested Shares, ending balance (in shares)	121,858	66,841
Weighted Average Grant Date Fair Value Per Share
Weighted Average Grant Date Fair Value Per Share, beginning balance (in dollars per share)	$ 24.04	$ 24.04
Granted (in dollars per share)	11.23	0
Forfeited (in dollars per share)	0	24.03
Weighted Average Grant Date Fair Value Per Share, ending balance (in dollars per share)	$ 18.26	$ 24.04

Warrants - Narrative (Details) - Warrants Issued in Connection with the Merger - $ / shares	Sep. 30, 2023	Dec. 31, 2022	Sep. 30, 2022	Dec. 31, 2021	Mar. 17, 2021
Class of Warrant or Right [Line Items]
Purchase price of warrant (in dollars per share)	$ 24.00	$ 24.00	$ 24.00	$ 24.00
Merger with Target
Class of Warrant or Right [Line Items]
Number of warrants to purchase (in shares)					602,392
Purchase price of warrant (in dollars per share)					$ 24.00

Warrants - Warrant Activity (Details) - Warrants Issued in Connection with the Merger - $ / shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Number of Warrants
Number of Warrants Exercisable, beginning balance (in shares)	602,392	602,392
Number of Warrants Granted (in shares)	0	0
Number of Warrants Exercised (in shares)	0	0
Number of Warrants Exercisable, ending balance (in shares)	602,392	602,392
Weighted Average Exercise Price
Warrants Exercisable, Weighted Average Exercise Price, beginning (in dollars per share)	$ 24.00	$ 24.00
Warrants Granted, Weighted Average Exercise Price (in dollars per share)	0	0
Warrants Exercised, Weighted Average Exercise Price (in dollars per share)	0	0
Warrants Exercisable, Weighted Average Exercise Price, ending (in dollars per share)	$ 24.00	$ 24.00

Stockholders' Equity - Narrative (Details)		3 Months Ended		9 Months Ended
Stockholders' Equity - Narrative (Details)	Aug. 13, 2021 $ / shares shares	Sep. 30, 2023 USD ($) $ / shares shares	Sep. 30, 2022 USD ($) shares	Sep. 30, 2023 USD ($) $ / shares shares	Sep. 30, 2022 USD ($) shares	Sep. 15, 2023 USD ($)	Dec. 31, 2022 $ / shares shares	Nov. 07, 2022 USD ($)
Preferred Units [Line Items]
Preferred stock, shares authorized (in shares) \| shares		100,000,000		100,000,000			100,000,000
Preferred stock outstanding (in shares) \| shares		0		0			0
Common stock, par value (in dollars per share) \| $ / shares		$ 0.01		$ 0.01			$ 0.01
Stock repurchase program authorized amount						$ 10,000,000		$ 10,000,000
Shares repurchased (in shares) \| shares				713,831
Average cost per share (in dollars per share) \| $ / shares				$ 12.96
Repurchase of common stock		$ 7,920,000		$ 9,254,000
Remaining availability under the program		$ 10,700,000		$ 10,700,000
Conversion ratio			1		1
NewLake Capital Partners Inc \| Merger with Target
Preferred Units [Line Items]
Shares issued (in shares) \| shares	3,905,950
Common stock, par value (in dollars per share) \| $ / shares	$ 0.01
Common Stock
Preferred Units [Line Items]
Shares repurchased (in shares) \| shares		608,152		713,831
Repurchase of common stock		$ 6,000		$ 7,000
OP Units Converted (in shares) \| shares		0	0	0	79,721
Restricted Stock Units (RSUs) And Performance Stock Units (PSUs)
Preferred Units [Line Items]
Unearned dividend equivalents		$ 348,302	$ 126,754	$ 348,302	$ 126,754
Restricted Stock Units (RSUs)
Preferred Units [Line Items]
Payment of dividend equivalent		0	10,116	35,264	17,628
Unearned dividend equivalents		88,756	35,850	88,756	35,850
Performance Stock Units (PSU)
Preferred Units [Line Items]
Unearned dividend equivalents		$ 0	$ 0	$ 0	$ 0
Series A Preferred Stock
Preferred Units [Line Items]
Preferred stock outstanding (in shares) \| shares		0		0

Stockholders' Equity - Common Dividends, Dividend Equivalents and Distributions Declared (Details) - $ / shares							9 Months Ended
	Sep. 15, 2023	Jun. 15, 2023	Mar. 07, 2023	Sep. 15, 2022	Jun. 15, 2022	Mar. 15, 2022	Sep. 30, 2023	Sep. 30, 2022
Stockholders' Equity Note [Abstract]
Amount per Share/Unit	$ 0.39	$ 0.39	$ 0.39	$ 0.37	$ 0.35	$ 0.33	$ 1.17	$ 1.05

Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Numerator:
Net Income Attributable to Noncontrolling Interests	$ 5,958	$ 6,510	$ 17,623	$ 15,285
Add: Net Income Attributable to Noncontrolling Interest	108	113	312	262
Net Income	$ 6,066	$ 6,623	$ 17,935	$ 15,547
Denominator:
Weighted Average Shares of Common Stock Outstanding - Basic (in shares)	21,199,638	21,428,905	21,330,046	21,417,149
Weighted Average Shares of Common Stock - Diluted (in shares)	21,582,314	21,802,487	21,710,101	21,815,763
Earnings Per Share - Basic
Net Income Attributable to Common Stockholders, Basic (in dollars per share)	$ 0.28	$ 0.30	$ 0.83	$ 0.71
Earnings Per Share - Diluted
Net Income Attributable to Common Stockholder, Diluted (in dollars per share)	$ 0.28	$ 0.30	$ 0.83	$ 0.71
Restricted Stock Units (RSUs)
Denominator:
Dilutive Effect of Unvested Restricted Stock Units (in shares)	9,094	0	6,473	0
OP Units
Denominator:
Dilutive Effect of OP Units (in shares)	373,582	373,582	373,582	398,614

Fair Value Measurements (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Carrying Value
Note Receivable	$ 5,000	$ 5,000
Revolving Credit Facility	1,000	1,000
Seller Financing	997	1,986
Fair Value, Inputs, Level 3
Estimated Fair Value
Note Receivable	4,800	4,952
Fair Value, Inputs, Level 2
Estimated Fair Value
Revolving Credit Facility	952	915
Seller Financing	$ 980	$ 1,942

Commitments and Contingencies (Details) $ in Millions	Sep. 30, 2023 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Unfunded commitments	$ 20.2

Subsequent Events (Details) - USD ($) $ in Thousands	1 Months Ended		9 Months Ended		12 Months Ended
Subsequent Events (Details) - USD ($) $ in Thousands	Nov. 09, 2023	Oct. 31, 2023	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Nov. 30, 2023
Subsequent Event [Line Items]
Payments for tenant improvements			$ 5,609	$ 43,518	$ 45,245
Proceeds from sale			0
Investment in property			374,553		$ 379,738
Mint Massachusetts Property
Subsequent Event [Line Items]
Investment in property			$ 1,900
Subsequent Event \| Revolutionary Clinics
Subsequent Event [Line Items]
Percentage of equity received						9.95%
Subsequent Event \| Mint Massachusetts Property
Subsequent Event [Line Items]
Proceeds from sale		$ 2,000
Cultivation Facility In Arizona And Missouri \| Subsequent Event
Subsequent Event [Line Items]
Payments for tenant improvements	$ 2,900
Cultivation \| Subsequent Event \| Revolutionary Clinics \| Massachusetts
Subsequent Event [Line Items]
Extension term (in years)		5 years
Proceeds from unpaid rent		$ 480
Security deposit		$ 315
Cultivation \| Subsequent Event \| Revolutionary Clinics \| Massachusetts \| Forbearance Agreement
Subsequent Event [Line Items]
Right of use asset under forbearance agreement						$ 2,000

NewLake Capital Partners (QX) (USOTC:NLCP)
Historical Stock Chart
Von Nov 2024 bis Dez 2024

Click Here for more NewLake Capital Partners (QX) Charts.

NewLake Capital Partners (QX) (USOTC:NLCP)
Historical Stock Chart
Von Dez 2023 bis Dez 2024

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

NLCP NewLake Capital Partners Inc (QX)

News NewLake Capital Partners Inc (QX)

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

NLCP NewLake Capital Partners Inc (QX)

News NewLake Capital Partners Inc (QX)

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen